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1 Abstract 
 Rationale 
Pneumococcal pneumonia is a leading cause of death globally, and susceptibility to invasive and 
pulmonary infection is increased in chronic respiratory conditions. Pneumococcal colonisation of the 
nasopharynx necessarily precedes disease, but the relationship of colonisation with Streptococcus 
pneumoniae and chronic respiratory disease (such as asthma) is unknown. Asthma is a heterogenous 
condition representing several phenotypes which have corresponding clinical characteristics and 
responses to therapy. Immune responses mediated by cytokines from cells such T helper cells 2 
(Th2) and Th17 lead to airway inflammation. Both this inflammatory pathology, and the treatment of 
it (with inhaled corticosteroids) potentially affect nasopharyngeal colonisation with S.pneumoniae. 
Hypothetically, airway inflammation might increase the potential for bacterial attachment, or 
increase bacterial clearance, or both. As nasopharyngeal colonisation is immunogenic in healthy 
adults, the balance of these opposing mechanisms may impact the resulting immune response. We 
have safely used the experimental human pneumococcal challenge (EHPC) model in healthy 
individuals to study nasopharyngeal colonisation and its associated mucosal and systemic immune 
responses.  
 Objectives 
Using experimental pneumococcal challenge in people with asthma, I examined the acquisition of 
nasopharyngeal colonisation of Streptococcus pneumoniae, its association with clinical 
characteristics, and systemic immune responses. I compared the results with historic data from 
earlier EHPC studies of healthy controls. 
 Methods 
I enrolled people with physician-diagnosed, well-controlled asthma on maintenance inhaled 
corticosteroids. Participants were challenged with pneumococcus serotype 6B, as this is not isolated 
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from nasal samples within the local community. Blood and mucosal samples were collected at 
baseline and on days 2,7, 9, 14, 22 and 29 after challenge. The results were compared to healthy 
controls from 4 experimental human challenge studies, with 2 performed concurrently and 2 in 
previous years. 
 Main Results 
Experimental colonisation rates were not significantly increased in people with asthma compared to 
healthy controls. The number of colonised participants (nasal wash positive for bacterial culture at 
any time point) was 28 (56%) in asthma vs 68 (45%) in healthy controls (Pearson’s chi square 
p=0.178). The density calculated using the area under time cure (AUC) was similar in people with 
asthma compared to healthy controls (median [IQR] asthma 63.49 [14.04-116.3] vs healthy controls 
81.18 [48.15-104.5] Mann Whitney U test p=0.060). Acquisition of colonisation was independent of 
baseline characteristics such as blood eosinophils and fractional exhaled nitric oxide levels. 
The duration of experimental colonisation was significantly shorter in asthma compared to healthy 
controls (median [IQR] 14 [7-29] vs 29[14-29]) p=0.034 Mann Whitney U test. Colonisation led to an 
increase in IgG titres to capsular polysaccharide and pneumococcal proteins in people with asthma 
as previously described in healthy controls.  
Body mass index correlated positively with likelihood of colonisation in people with asthma. Median 
BMI for the whole cohort was 24.6 (IQR) (21.6-27.5), with colonised participants (nasal wash positive 
for bacterial culture at any time point) having a higher BMI median 24.7 (24.1-29.0) vs 23.5 (20.1-
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Experimental colonisation is not affected by clinical characteristics of asthma, and it is positively 
correlated with a high BMI. The rate and density of experimental nasopharyngeal colonisation in 
people with asthma are similar as seen in healthy controls. The duration of colonisation is 
significantly reduced in people with asthma compared to healthy controls, with a similar 
immunogenic effect as seen in healthy controls. 
Interventions to reduce the likelihood of severe and invasive pneumococcal disease, to which people 
with asthma are more prone, could be targeted at specific sub-groups. Further investigation could 
suggest if those with higher BMI should have a lower threshold for vaccination. 
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2 Introduction 
Pneumonia is a common condition and disproportionately affects people at the extremes of age, the 
immune compromised, and those with chronic respiratory conditions (1, 2). Asthma predisposes to 
pneumonia, but the magnitude and mechanism of effect are not fully elucidated.  
Pneumonia remains a leading cause of morbidity and mortality worldwide, with the burden of 
disease being greatest in low and middle-income countries (LMIC) (3). It accounts for more deaths in 
children under the age of five than any other illness. The commonest cause of bacterial pneumonia 
is Streptococcus pneumoniae, resulting in approximately 40,000 hospitalisations and 70,000 primary 
care consultations annually in the United Kingdom (4). S. pneumoniae is commonly found in the 
nasopharynx, the source of primary spread (5) and initial step towards infection (6). Colonisation is 
most prevalent in children (7, 8) and declines with increasing age (9), probably due to acquired 
immunity from exposure. Nasopharyngeal colonisation is a dynamic process with changing 
prevalence, density and serotype of S. pneumoniae. A high colonisation density in the nasopharynx is 
associated with subsequent development of pneumonia (10), and replacement with more virulent 
serotypes may lead to pneumonia (11). Perturbation of the airway microbiome may also lead to 
pneumococcal pneumonia, in some cases without dense nasal colonisation (12, 13). 
Systemic immune responses are robustly generated following pneumococcal vaccination, which is 
now part of the childhood immunisation programme in around half of World Health Organisation 
member states (14, 15). Vaccination is associated with a reduction in hospitalisations due to 
pneumonia in children and adults (16), and is effective in reducing the risk of invasive pneumococcal 
disease (17, 18). However, the incidence of pneumonia is increasing in the elderly (19, 20). 
Preventing colonisation is therefore an important alternative target for controlling pneumococcal 
transmission (6), reducing the incidence of respiratory tract conditions (sinusitis, otitis media and 
pneumonia) and invasive disease (septicaemia and meningitis) (21) in those most at risk. 
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Patients with mild, moderate and severe asthma suffer from exacerbations which are mostly due to 
viral infections (22) but can be secondary to bacteria such as S. pneumoniae; the commonest cause 
of pneumonia. Several risk factors are identified for nasopharyngeal colonisation of S. pneumoniae 
(23) including asthma and an asthma exacerbation in the previous twelve months. Inhaled 
corticosteroids (ICS) are the mainstay of treatment for asthma, and escalating doses are 
recommended to achieve adequate control (24). Recent evidence from studies of chronic 
obstructive pulmonary disease (COPD) suggests ICS therapy increases the risk of pneumonia (25), 
and has led to a change in guidelines for COPD, which now advise discussion of the increased risk of 
pneumonia secondary to ICS with patients, and consideration of other therapies (26). There is 
conflicting evidence in asthma, with review of data from randomised controlled trials showing no 
increased risk, and observational studies reporting an increased prevalence of pneumonia and 
invasive pneumococcal disease (27-30).  
The focus of this thesis is to determine the rate of experimental nasopharyngeal colonisation of 
Streptococcus pneumoniae in people with asthma, and to understand systemic and mucosal immune 
responses following colonisation in comparison to healthy controls.  
  Asthma  
  Definition 
Asthma is a chronic inflammatory condition, clinically characterised by episodes of recurrent 
wheeze, shortness of breath, chest tightness and cough secondary to airway hyper responsiveness 
(AHR). These symptoms often occur at night or early morning, and are associated with airway 
obstruction which is variable and reversible either spontaneously or with treatment (31).  
 Aetiology 
The exact aetiology of asthma is not clear with several factors contributing to the pathophysiology of 
this chronic condition. It is increasingly recognised as a complex syndrome with genetic 
predisposition and more than 100 identifiable gene associations (32, 33). The disease contributing 
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factors can be broadly grouped into two: i) related to the host such as genetic predisposition and ii) 
related to symptom triggers or sensitisation such as environmental factors (31). Prenatal factors 
such as maternal smoking, diet, stress, use of antibiotics and mode of delivery by caesarean section 
have all been associated with development of atopic disease including wheeze in early childhood 
(34). In addition, exposure to infections, tobacco smoke, use of antibiotics in early life, having low 
lung function, being breast fed or not, socio-economic status, allergic sensitisation, and exposure to 
animals can all modify the risk of developing asthma in genetically predisposed individuals (34, 35). 
Adults may develop asthma secondary to occupational exposure, from smoking tobacco and other 
recreational drugs (34). Complex interactions between host and environmental factors are an area 
of interest for research and further investigation (36). 
 Asthma Phenotypes 
Severe asthma requires treatment with high dose ICS plus a second controller and systemic 
corticosteroids to achieve symptom control and may remain uncontrolled despite this therapy. 5-
10% of total asthma burden is estimated to be that of severe asthma (37). Asthma is well 
appreciated for its heterogeneity with variable clinical presentation and differing response to 
therapy. Phenotypes refer to observable clinical and treatable characterstics resulting from 
hereditary and environmental factors. There is increasing interest in understanding asthma 
endotypes - the underlying molecular and patholophysiologic mechanisms which determine clinical 
characterstics and response to treatment. Accessibility to biological therapy for treatment of asthma 
and approach to personalised medicine has further enhanced research interest in endotypes (38).  
Personalised medicine has lead to the concept of treatable traits for airways disease such as 
presence of eosinophilc airway inflammation, increased smooth muscle contractility and reversibility 
(39). This is an evolving concept with suggestions that these can be used to predict future 
exacerbations and improve outcomes by providing targeted therapy specially in severe asthma (40). 
Severe asthma phenotypes are classified either according to clinical characteristics or by 
pathobiological differences in sputum or bronchoscopy samples (41). Another approach to 
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classification includes triggers for the disease, such as environmental allergens or occupational 
exposures (42). Although classifications aim to define and distinguish phenotypes from each other, 
significant overlap is seen across groups. 
2.1.3.1 Eosinophilic Asthma Phenotype 
This is characterised by eosinophilic airway inflammation driven by T helper type 2 (Th2) cells and 
interleukin 5 (IL5) (43). In severe uncontrolled asthma eosinophilia is present in the airway mucosa 
of both upper and lower respiratory tract, and high counts are seen in sputum and bronchial 
samples (44, 45). Eosinophils are produced in response to inflammatory mediators released by Th2 
cells such as IL5, IL13, and granulocyte colony stimulating factor (GCSF). These are recruited to the 
airways and act on mast cells to release histamine leading to airway hyper responsiveness, increase 
mucus production by goblet cells, eosinophil peroxidase causing epithelial cell damage and 
transforming growth factor β (TGFβ) leading to airway remodelling (46, 47). Eosinophilia is an early 
sign of an asthma exacerbation and patients with eosinophilic asthma experience recurrent 
exacerbations (48). Eosinophilic inflammation leads to basement membrane thickening and may 
result in fixed airflow obstruction.  
2.1.3.1.1 Fractional Exhaled Nitric Oxide (FENO) can be used to identify eosinophilic asthma 
Nitric oxide (produced by the conversion of L-arginine to L-citrulline, catalysed by NO synthases 
(NOS)) is an important inflammatory mediator in the lungs and acts as a vasodilator, bronchodilator 
and non-adrenergic and non-cholinergic neurotransmitter (49, 50). It is produced by epithelial cells, 
macrophages and T lymphocytes in the lungs (51). High levels of Fractional Exhaled Nitric Oxide 
(FeNO) noted in eosinophilic phenotype are associated with worse asthma control and peripheral 
blood eosinophilia. FeNO is reduced by steroid treatment (52). It is a simple non-invasive 
measurement of airway inflammation widely used in clinical practice (53). The values are recorded in 
parts per billion (ppb) (54). 
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2.1.3.2 Obesity related asthma  
Obesity is recognised as a risk for asthma and can be secondary to a high body mass index (BMI) or a 
consequence of therapy for the condition (55). Excessive maternal weight gain during pregnancy 
may lead to an increased risk of asthma in future for the baby (56, 57).  The prevalence of asthma is 
increased in adults with a high BMI compared to those within normal range (58). Obese patients 
have more severe asthma, increased hospitalisations, poor symptom control and worse quality of 
life (59, 60). The response to usual asthma therapy is suboptimal in obese patients due to an altered 
cytokine profile (61). Obesity alters Th2 driven inflammation by affecting eosinophil recruitment, 
with an increase in sputum IL5 and submucosal eosinophils, but does not affect sputum eosinophils 
(62). Obesity alters innate immune responses in the upper (innate lymphoid cells and macrophages) 
and lower respiratory tract (surfactant protein A) (63, 64). Lung function is altered by obesity itself 
with a noticeable reduction in expiratory reserve volume (ERV), and an increase in AHR (65, 66). 
Clinically, weight loss is associated with improvement in not only asthma severity, control, but also 
quality of life (55). 
  Asthma Diagnosis 
Asthma is a syndrome with variable presentations and symptoms. The diagnosis is often challenging, 
based on clinical history, examination and diagnostic tests. The tests can measure clinical 
parameters such as lung function, reversibility and peak flow rates and airway hyper-responsiveness 
or determine airway inflammation and allergic status (31).  
2.1.4.1 Clinical History and Physical Examination 
Symptoms of episodic wheeze, cough, shortness of breath suggest a clinical diagnosis of asthma (67). 
These can show seasonal and diurnal variation, and often occur in response to allergen exposure. In 
addition, a family history of asthma, and history of atopic disease can be helpful. Presentations and 
symptoms are variable; patients may present with symptoms related to exercise only, and some 
with predominant cough often at night only (68). The symptoms can fluctuate over days, months, 
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seasons or at different times of the day. This is an important part of asthma diagnosis and 
specifically enquired from the patients (31). Physical examination can be completely normal with 
polyphonic wheeze being the most common finding (31).  
2.1.4.2 Diagnostic Tests 
2.1.4.2.1 Lung Function Measurements: Reversibility and Peak Expiratory Flow Variability 
These are performed and repeated on different visits, with adequate instructions by trained staff to 
ensure good quality results (69, 70). A change in forced expiratory volume in one second (FEV1) of 
>200mls and >12% after inhaled bronchodilator (salbutamol 200-400mg) is an accepted indication of 
asthma (71), although lacking sensitivity. An absence of reversibility is seen in patients on optimal 
treatment with good symptom control, and does not exclude asthma (31).  
Peak expiratory flow rate (PEF) is another useful measurement for diagnosis and monitoring of 
asthma. These are effort dependent and values differ for different peak flow meters and therefore 
can only be used in addition to spirometry and not in place of it (31, 72). Comparison is made with 
the patient’s best reading, obtained at a time when they are well and symptom free. Airway 
obstruction may reverse over time after initiation of appropriate treatment such as ICS (31).  
2.1.4.2.2 Bronchial Provocation Testing  
This test measures bronchial hyper responsiveness (BHR). Inhalation of histamine, methacholine or 
mannitol is monitored by serial spirometry, starting at a very low concentration and gradually 
increasing. After each dose FEV1 is compared to baseline. 
This is helpful in assessing individuals with symptoms suggestive of asthma with normal lung 
function (31). Methacholine challenge test has a better negative predictive value and is therefore 
useful to exclude a diagnosis of asthma (73). The test should be performed by adequately trained 
professionals as it can cause bronchoconstriction. It is interpreted according to the value of 
provocation concentration producing a fall of 20% (PC20) (mg/ml) with >16 accepted as normal, 4-6 
borderline, 1-4 mild and <1 moderate to severe BHR (73). This test was considered but not used for 
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diagnosis in our study, for two reasons: i) It leads to aiway inflammation and may have resulted in an 
exacerbation. They may have required treatment with OCS and deferred for 4 weeks, ii) it is 
expensive and the cost of the test was not included in the overall expenses for the study, we did not 
have funding for this.  
2.1.4.2.3 Fractional Exhaled Nitric Oxide (FeNO) 
See section 2.1.3.1.1. 
 Airway microbiome in asthma 
Advances in novel culture-independent techniques to identify bacteria, have improved our 
understanding of the different human microbiota (74). Pyro sequencing of 16S rRNA gene amplicons 
from bacteria helps in genus and species identification (75, 76).  
The upper and lower airway microbiome is different, with the latter studied using bronchoalveolar 
lavage (BAL) specimens, and/or in spontaneously expectorated sputum (74) (77, 78).  
Bacteria from the phylum proteobacteria (H.influenzae, M.catarhalis, Neisseria spp) are significantly 
increased in asthma compared to healthy controls and COPD in the oropharynx (79). Genus 
Haemophilus is present in both COPD and asthma in samples from the bronchial tree (BAL and 
bronchial brushings) (78). 
Airway microbial composition and diversity (variation in species in mild, moderate and severe 
asthma) is correlated to bronchial hyper responsiveness in sub-optimally controlled asthma (80). 
Specific bacterial groups such as Nitrosomonas species with the enzyme nitric oxide reductase (81) 
may alter nitric oxide concentration and FeNO levels (82, 83), and the microbiome may influence 
corticosteroid sensitivity (84).  
 Asthma Exacerbations 
A severe asthma exacerbation is an acute episode of progressive worsening of symptoms, including 
shortness of breath, wheezing, cough, and chest tightness, requiring treatment with oral 
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corticosteroids or an increase from a stable maintenance dose for a period of 3 days or more (85). 
Moderate asthma exacerbations do not require treatment with systemic corticosteroids, are 
associated with a deterioration in symptoms and treated with a temporary increase in inhaled 
therapy such as increased use of salbutamol (85). 
 Viral causes of asthma exacerbation  
Most acute asthma exacerbations are caused by viruses (86, 87), and human rhinovirus is the 
commonest implicated organism (88). Antibiotics are not recommended routinely for the treatment 
of acute asthma exacerbation (24) and are usually prescribed to treat exacerbations for patients 
with a diagnosis of COPD or both COPD and asthma, as opposed to those with a diagnosis of asthma 
alone (89).  
 Bacterial causes of asthma exacerbation 
Bacteria are recognised as a source of infection, exacerbation (90) and colonisation of airways in 
asthma (91), although viral infections are accepted as the primary cause (92). Bacteria are also found 
in sputum of patients with asthma outside of an exacerbation (91). This is further discussed in 
section 2.5 
 Managing Asthma 
 Inhaled Corticosteroids (ICS) are the mainstay of preventative treatment 
of asthma 
ICS have anti-inflammatory properties improve symptoms, quality of life and lung function (31) (93). 
They help control airway inflammation, reduce airway hyper-responsiveness, frequency and severity 
of exacerbations along with mortality (93-96). The available ICS for treatment of asthma are shown 
in Table 1. These are usually started in low doses and increased as required to achieve optimal 
control (24); high doses are associated with side effects (97, 98). The dose delivered varies for 
different formulations and devices. ICS therapy does not cure asthma and symptoms may 
deteriorate when patients stop taking these (99). 
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Table 1 Commonly used ICS  
 ICS Brand names available 
1 Beclomethasone dipropionate Clenil Modulite®, Qvar®, Fostair® 
2 Budesonide Pulmicort®, Symbicort® 
3 Ciclosenide Alvesco® 
4 Fluticasone propionate Seretide®, Flixotide 
5 Mometasone acetonide Asmanex® 
6 Fluticasone furoate  Relvar® 
Fostair, Symbicort, Seretide and Relvar are combination inahlers with long acting beta agonist.  
2.3.1.1 Common Side Effects of ICS 
High doses of ICS can be associated with local (oral thrush) and systemic side effects (85) such as 
adrenal suppression, bruising, reduced bone mineral density, cataracts and glaucoma (100-107) 
 Long Acting Beta agonist (LABA) 
These are used as add on therapy to ICS for better symptom control (85). Combination of ICS and 
LABA is initiated when treatment with low to medium dose of inhaled corticosteroids is not 
sufficient to control symptoms (108). This is an effective combination and leads to improvement in 
symptoms, lung function, reduction in exacerbations and use of short acting beta agonist (SABA) (95, 
109-113), and is the preferred option when a medium dose of inhaled corticosteroids alone fails to 
achieve control.  
 Leukotriene Receptor Antagonists (LTRA) 
In the airway leukotrienes cause smooth muscle contraction, lead to increased mucus production, 
reduced muco-ciliary clearance and enhanced eosinophil recruitment (114-116). LTRA have a 
variable response in asthma and BTS recommends a trial of LTRA if addition of LABA to ICS therapy 
does not provide adequate symptom control (24) (117).  
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 British Thoracic Society Treatment Steps 
Asthma treatment is increased to improve symptom control in a stepwise manner in accordance 
with the British Thoracic Society (BTS) guidelines (24). The steps are described in Table 3. Patients on 
step 1 are only treated with as required short acting beta agonist (SABA). ICS in a low dose is added 
at step 2. If symptoms persist ICS dose is increased, with addition of LABA and LTRAs. Patients on 
step 4 require high dose ICS and often multiple courses of oral corticosteroids (OCS), and on steps 5 
are prescribed regular maintenance OCS. This approach is helpful in distinguishing patients with 
severe disease – on step 4 and 5, who may be eligible for new therapies such as monoclonal 
antibodies – which may reduce the use of OCS and achieve better asthma control with a reduction in 
exacerbations (118, 119). These guidelines were updated in 2019 and use of SABA is no longer 
recommended, instead low dose ICS therapy is advised as an initial treatment. The new guidance 
recommends referral to specialist centre for patients on high dose ICS with persistent uncontrolled 
symptoms (24). 
 Streptococcus pneumoniae 
S.pneumoniae are gram positive cocci, with a polysaccharide capsule and a cell wall made up of 
peptidoglycans and teichoic acid (21). The capsule is an important determinant of the virulence for 
S.pneumoniae, with up to 90 different polysaccharides identified on the surface. These are different 
structurally and prevent phagocytosis of bacteria by generating a specific immune response, unique 
to the respective polysaccharide (5), with limited cross antigenicity due to shared polysaccharide 
epitopes (120). The 23-valent polysaccharide vaccine (PPV 23) is designed to cover serotypes causing 
the vast majority of infections (121).  
The bacterial cell wall lies beneath the polysaccharide capsule and plays an important part in 
generating an inflammatory response by initiating recruitment of leukocytes, inducing cytokine 
production and increasing vascular permeability (120). It is a dynamic structure with embedded 
pneumococcal surface proteins (6), of which several are identified as potential vaccine targets.  
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Unlike the capsular polysaccharides, pneumococcal proteins are not serotype specific. Several 
proteins are identified on the surface of S.pneumoniae, with many found in all the clinically relevant 
strains (122). These factors make them a suitable target for novel vaccines, which would provide 
protection against more serotypes than the currently available vaccines and may help overcome the 
challenge of serotype replacement. An increase in antibody titres to pneumococcal proteins is seen 
in infants between the ages of 12 and 24 months naturally regardless of colonisation status, and in 
response to colonisation (123). These antibody titres do not provide protection against future 
colonisation episodes and are inversely related to age (123). 
Pneumococcal choline-binding protein A (PcpA), genetically detoxified pneumolysin (PlyD1, PdA, 
PdB), chemically detoxified pneumolysin (dPly), and Pneumococcal histidine triad D (PhtD) and E 
(PhtE) have been widely studied. Phase II clinical trials have been performed with formulations of 
monovalent PhtD, PlyD1, PcpA or bivalent PhtD-PcpA proteins. Results from phase I studies show 
these formulations to be safe and immunogenic (124).  
Choline binding proteins (CBP) help in adherence of the bacteria to the surface receptors such as the 
platelet activating factor receptor (PAFR) and provide assistance in the acute phase response (125).  
Pneumococcal biofilms are structured cellular aggregates seen during nasopharyngeal colonisation 
and diseases such as sinusitis (126) . The cluster of cells in close proximity facilitates transfer of 
genetic material, this may help  biofilms promote antimicrobial resistance (127, 128). Antibiotic 
resistance may be attributed to a change in phenotype of the bacteria, secondary to transfer of 
genetic information as well as reduced penetration. Biofilms may cause upward or downward 
regulation of genes with inclusion of competence stimulating protein leading to an increase in 
biomass. During interaction with the epitehlial cells pneumococci down regulate their capsule which 
is facilitated by biofilms  Environmental factors such as nutrient availbilty and temperature are the 
major determinants of biofilm formation (129). Both ICS and the excipients in inhaled powders may 
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affect biofilm formation in people with asthma (130). Biofilm formation may lead to worse outcome 
secondary to genetic transformation and anti microbial resistance (126). 
 Pneumococcal Colonisation is More Common in People 
with Asthma  
  Early life pneumococcal colonisation and subsequent asthma 
Infants colonised with S. pneumoniae have a two to four-fold increased risk of a first wheezy 
episode, persistent wheeze, development of asthma by the age of 5 years, and hospitalisations for 
wheeze. Early nasopharyngeal colonisation is associated with an increased eosinophil count, IgE and 
airway reversibility. This was demonstrated by the Copenhagen Prospective Study on Asthma in 
Childhood (COPSAC), an ongoing clinical, prospective, longitudinal birth-cohort of infants born to 
mothers with current or previous asthma. 321 of these infants had hypopharyngeal swabs collected 
at the age of 1 and 12 months, and bacteria were isolated using microbiological culture techniques. 
All the infants were asymptomatic at the time of sample collection. The overall prevalence of one or 
more organism was 71% including S. pneumoniae, M. catarrhalis, H. influenzae (35). 
The prevalence of asthma in the overall cohort at 5 years of age was 14%, but 33% of those initially 
colonised were diagnosed with asthma. Blood eosinophil count and total IgE were significantly 
higher in colonised children at the age of 4 years (35). Early life nasopharyngeal colonisation of S. 
pneumoniae is associated with asthma later in life. 
  Pneumococcal colonisation and current asthma  
An increased prevalence of S. pneumoniae colonisation has been seen in people with asthma in 
observational studies (23, 131, 132). An Italian study investigated S. pneumoniae colonisation in 
children and adolescents with asthma by collecting oropharyngeal swabs at one time point and 
analysing them using polymerase chain reaction (PCR) for the autolysin-A-encoding (lytA) and the 
wzg (cpsA) gene of S. pneumoniae. (132). The colonisation rate of 45% is similar to those seen in 
other observational studies in young children (133). Esposito et al (132) performed this study when 
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PCV-7 had been part of the immunisation schedule for five years in Italy and included children 
regardless of their vaccination status. There was no association between vaccination and 
nasopharyngeal carriage (48% vs 43% vaccinated compared to non- vaccinated), though time since 
vaccination was not studied. Parental smoking, recent use of systemic corticosteroids, and the 
severity of asthma did not affect carriage rates. A total of 423 children were enrolled with varying 
degree of disease severity. Results are described in the Figure 1:  
 
Figure 1: Nasopharyngeal carriage rates in children with asthma; comparison of rates in vaccinated 
and unvaccinated groups  
(adapted from data Esposito et al (132). 
A case control study of army recruits found a two-fold increased prevalence of S. pneumoniae 
colonisation in those with well-controlled, mild to moderate physician diagnosed asthma (n=224) in 
comparison to those without asthma (n=668) (134). Study participants were asked to complete a 
questionnaire on medical history and allergy status, and oropharyngeal swabs were collected within 
the first two weeks of service. Just under half of those with asthma were on medication for the 
condition (107, 48%), and this did not influence colonisation rates observed in this study (134). 
Microbiological culture was used to identify the organisms. No objective evidence of asthma or data 
on compliance with medication or smoking history was available. 
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Having an asthma exacerbation in the previous 12 months is associated with an increased risk of 
pneumococcal colonisation. A cross-sectional population-based study of over 1000 adolescents in 
Brazil found a nasopharyngeal colonisation rate of 19% (OR=2.89) in the 37 participants who had 
experienced an acute exacerbation of asthma in the previous 12 months (131). Sinusitis and rhinitis 
were associated with nasopharyngeal colonisation, both of which are common comorbidities in 
asthma (135).  
In summary, pneumococcal colonisation appears more common in people with asthma, especially in 
individuals with a recent asthma exacerbation and possibly those with concurrent nasal symptoms. 
  Pathophysiological factors affecting colonisation rates in asthma  
In this section, I discuss some aspects of the immune system which mediate airway inflammation in 
asthma and may influence pneumococcal colonisation and clearance in the nasopharynx. 
2.5.3.1  Airway Inflammation 
The hallmark of asthma is chronic airway inflammation mediated by innate and adaptive 
mechanisms (136). This causes differential damage throughout the airway epithelium (137), and 
biopsies show epithelial inflammation in patients across the spectrum of disease. Surface epithelial 
thickening, metaplasia, goblet cell hyperplasia, increased mucus secretion with altered density, and 
hypertrophy of smooth muscles can be present (138). Chronic inflammation secondary to 
eosinophils is seen in the nose and plays a part in development of nasal polyps (139). This is 
associated with higher pneumococcal colonisation due to increased sites for bacterial attachment 
(140) including the epithelial surface expression of platelet activating factor receptor (PAFR) (141). 
Pneumococcus binds to PAFR through phosphoryl choline in its cell wall (142). PAFR is upregulated 
during viral infections and secondary to other inflammatory stimuli, including asthma (143). It is 
itself an important pro-inflammatory mediator which contributes to asthma pathogenesis by 
activating immune cells, causes chemotaxis of eosinophils, increases vascular permeability, mucus 
production and bronchial constriction (144-146). PAFR antagonists represent potential therapies in 
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acute and chronic asthma (147). In vitro studies show that mice lacking PAFR are relatively protected 
against pneumococcal pneumonia (148). In another murine model, mice were sensitised by 
intraperitoneal injection of ovalbumin, and subsequently their sinuses were dosed with S. 
pneumoniae with concomitant administration of ovalbumin to induce local allergic inflammation. 
Infection with S.pneumoniae was increased in response to the allergic inflammation induced by 
ovalbumin (149). In summary, the type of airway inflammation seen in asthma appear to be 
associated with increased bacterial adherence and colonisation, and progression to infection.  
2.5.3.2  Capsular Polysaccharide Specific and Pneumococcal Protein Antibody  
Impaired antibody responses may account for increased rates of colonisation and risk of invasive 
pneumococcal disease in asthma.  
Pneumococcal capsular polysaccharide immunity is partially protective against nasopharyngeal 
colonisation. In a human infection model with pneumococcus, capsular polysaccharide (CPS) IgG-
mediated bacterial agglutination in the nasopharynx was observed in PCV-vaccinated adults and 
associated with protection against colonisation acquisition (150). PCV reduces serotype specific 
nasopharyngeal colonisation, probably resulting in herd immunity and protection from disease (151, 
152). In an observational study more than two thirds of patients with severe asthma were found to 
have low baseline antibody levels to S. pneumoniae and H. influenzae (153). 
In a cross-sectional study, levels of serotype-specific CPS antibodies were lower in children and 
adults with asthma compared with healthy volunteers. There was no difference in nasopharyngeal 
colonisation between the two groups (half of each group had been vaccinated) and their community 
exposure to S. pneumoniae is likely to have been equivalent. The median number of positive vaccine 
serotype specific antibodies in the PCV7 cohort was also lower in asthma when compared to healthy 
volunteers (5 vs 7 respectively p=0.046) (154). Additionally, an inverse relationship between 
interleukin 5/interferon gamma (IL5/IFN-g) (Th2 immune profile) in response to house dust mite 
stimulation of peripheral blood mononuclear cells (PBMCs) and the number of serotypes to which 
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antibodies increased above a certain threshold is seen in the asthma group (154). The same research 
group undertook a similar investigation comparing serum IgG to anti-pneumococcal surface protein 
in people with and without asthma: anti-pneumococcal surface protein C (Psp C) levels were 
inversely correlated with Th2 immune profile. PspC is an adhesin to polymeric immunoglobulin 
receptor (PIgR). This receptor helps bacterial adhesion to the nasopharyngeal epithelium, initiates 
colonisation and facilitates invasive disease (155). Antibodies against pneumococcal surface proteins 
may also have a protective role against bacterial nasopharyngeal colonisation and subsequent 
disease (156). Hales et al identified lower levels of IgG1 titres PspC and Haemophilus influenzae 
antigens P4 and P6 in children with asthma (157). Taken together, these results suggest an impaired 
immune response in people with asthma which may predispose to an increased risk of 
pneumococcal disease (158). 
2.5.3.3  Cytokine IL-17 
Advances in our understanding of heterogeneity of asthma have led to more tailored use of 
therapies such as anti-IL5 monoclonal antibodies, which can be effective in patients showing Th2 
cell-mediated inflammation. However, many people with asthma have at least some inflammation 
secondary to Th17 responses. This pathway appears more important in individuals who are older, 
obese and non-allergic (136). Th17 cells produce cytokines such as IL17 and IL22 (159). In mouse 
models of asthma, IL17 contributes to airway remodelling by promoting fibroblast proliferation (160) 
and opposing the anti-inflammatory features of T regulatory cells (161). It can also lead to direct 
contraction of smooth muscle leading to bronchial hyper responsiveness (162). IL17 secretion by 
Th17 cells is not inhibited by corticosteroids and this may explain the lack of improvement in 
symptoms of neutrophilic asthma with increasing dose of ICS (136, 163). 
Although IL17 is an important pro-inflammatory cytokine which promotes airway remodelling in 
asthma, it facilitates timely clearance of pneumococcal colonisation. IL17 secretion leads to 
neutrophil and macrophage recruitment and activation which in turn facilitates clearance of the 
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bacteria (164, 165). Th17 responses have been associated with acquired immunity to colonisation in 
mice models and control of duration and density of pneumococcal colonisation (165).  
Role of IL17 in mouse models suggests this may be a useful target for therapy in asthma. However, 
brodalumab a monoclinal antibody against IL17 receptor was not seen to improve either symptom 
control or lung function in patients with moderate to severe asthma on regular inhaled 
corticosteroids. A small subgroup of participants in the study with high reversibility (>20%) showed 
nominal improvement in Asthma control questionnaire score (ACQ). IL17 levels were not measured 
in the study, with atopy recorded as positive skin prick test seen in for 250 of the 302 participants. 
Therefore, it is plausible that the participants selected did not have underlying IL17 driven asthma 
(166). This would support further study of anti IL17 therapy in a selected subgroup of asthma 
patients, with more defined treatbale traits such as number of exacerbations and measurement of 
IL17 levels. 
Allergic inflammation involving Th2 cytokines is associated with reduced antimicrobial activity and 
diminished IL17 expression at the epithelial surface secondary to antimicrobial peptide human beta 
defensin (167). This is also seen in other allergic conditions such as atopic eczema, and associated 
with multiple and often persistent skin infections (168). A murine model studying the effect of 
allergic inflammation on innate immunity found increased viable bacteria (Pseudomonas aeruginosa, 
used for infecting mice) in the lungs of sensitised mice after bacterial exposure along with reduced 
antimicrobial activity (168). Reduced immune responses in allergic airway inflammation may lead to 
an increased risk of pneumonia. In mice models, exogenous IL17 improves host defences against S. 
pneumoniae, and reduces pulmonary eosinophil recruitment and bronchial hyper reactivity (169).  
The generalisation that Th17-driven asthma has better protection against pneumococcal infection, 
and allergic asthma predisposes to infections appears a useful construct. However it is evident that 
there is considerable overlap in these processes within individuals over time (136) and in the context 
of their differential response to corticosteroids (163). These findings emphasise that it is difficult to 
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make general statements regarding individuals with a clinical diagnosis of asthma without additional 
phenotypic investigation. 
2.5.3.4  Therapy with Corticosteroids 
Inhaled corticosteroids (ICS) are associated with an increased risk of pneumonia in patients with 
COPD (25). The commonly identified organisms in the study included S. pneumoniae, H. influenzae,  
Klebsiella pneumonia and Pseudomonas aeruginosa. They are the mainstay of treatment for asthma 
but could increase risk of infection by altering nasal colonisation or predisposing to infection if 
colonisation is present.  
In a large retrospective analysis of the manufacturer’s trial data, use of budesonide was not 
associated with increased risk of pneumonia (27). This study analysed double-blind placebo-
controlled trials as primary data set, including studies of both ICS, and ICS with long-acting beta-
agonist (LABA) as the active intervention. Pneumonia as an Adverse Event (AE) was observed in 0.5% 
of the budesonide cohort and 1.2% of the placebo group (95% CI 0.36–0.76; p<0.001) and was 
recorded as a Serious Adverse Event (SAE) in 0.15% of the budesonide group and 0.13% (95%CI 
0.53–3.12, p= 0.58) in the primary set (only 22 occurrences in almost 15000 individuals). In a 
secondary data set of 70 placebo or active comparator-controlled trials, pneumonia as an AE 
occurred in 0.70% and as an SAE in 0.17%.  
In contrast to controlled trial findings, a case-control study in the UK reported an increased risk of 
pneumonia and lower respiratory tract infection (LRTI) in asthma with any ICS (OR 1.96, 95% CI 1.15-
1.33) and further increased if on high dose ICS (>1000µg BDP equivalent) (OR 2.04 (95% CI 1.59-2.64) 
(28). Patients with a diagnosis of pneumonia or LRTI in the preceding 3 years were identified from a 
primary care database and matched by age and gender to controls from the same geographical area. 
ICS dose and type were identified from prescriptions in the preceding 90 days (170). Adjustments 
were made for lung function and asthma severity along with oral steroid use. Of the commonly used 
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asthma treatments, fluticasone was associated with the greatest risk of pneumonia (OR, 1.64; 95% CI 
1.50-1.79; P<0 .001), and budesonide with a modest risk (OR, 1.20; 95% CI 1.06-1.35; P<0.003) (28).  
The differences in the risk profiles for ICS may be explained by the differing pharmacokinetics and 
pharmacodynamics of this class of medication. The addition of esters and cyclic esters increases the 
affinity for glucocorticoid receptors. Fluticasone is not a pro drug and its efficacy depends on intact 
molecule, and duration of action is dependent on the pulmonary transit or residence time which is 
high for lipophilic molecules such as fluticasone furoate and fluticasone propionate. The increased 
risk of pneumonia associated with fluticasone may be explained by these characrterstics at the 
molecular level (171). 
An observational study from Brazil reported an increase in nasopharyngeal colonisation of S. 
pneumoniae in children with asthma taking ICS (172) compared with age-matched controls. The 
children were on treatment with ICS for at least 30 days (n=96) and the controls had no ICS for at 
least 90 days (n=96); rates of pneumococcal vaccination were similar in both groups (ICS group 19 
(19.8%) and controls 21 (21.9%). The pneumococcal colonisation was higher in the ICS group (27%) 
as compared to the controls (8%), p = 0.001 (95% CI 1.72-8.18). A high dose and an increased 
duration of ICS was associated with increased prevalence of pneumococcal colonisation (31.7% for 
400-800ug and >6 months treatment vs 19.4% for <100-300ug and <6 months). It is unclear whether 
higher dose ICS was causative or simply a marker of more severe asthma.  
The discrepancy between the highly selected population in trials with their restricted ecology of 
care, and observations from practice warrants significant further study in humans given the 
prevalence of ICS use and the potential for harm. 
When considering the effect of ICS on pneumococcal colonisation and infection, it should be 
remembered that inhaled corticosteroids are interacting with a broader airways’ microbiome. 
Pneumococcal colonisation is linked to airway microbiome diversity in healthy adults (173). The 
diverse airway microbiome in asthma with predominance of proteobacteria may influence the 
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nasopharyngeal carriage acquisition secondary to interactions between different species (173) and 
certainly appears to influence corticosteroid responsiveness (174).  
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Figure 2: Schematic diagram depicting the molecular interactions between S. pneumoniae and 
immune cells at the nasopharyngeal mucosa. 
Interleukin (IL) 17 and IL5 cause chemotaxis of inflammatory cells to the submucosa and mucosa 
causing airway inflammation. The Platelet activating factor receptor (PAFR) provides increased 
attachment sites for the bacteria. Inflammation driven by IL5 (Eosinophils), IL17 and PAFR all lead to 
bronchoconstriction, thereby playing a part in asthma pathophysiology. (NO – nitric oxide, ROS – 
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 Upper and Lower Respiratory Tract Immune Responses  
In the upper airway, mucosal innate immune response is dominated by bacterial phagocytosis by 
macrophages and neutrophils. Adaptive immune responses occur when T cells present antigen to B 
cells which produce specific antibodies to opsonise bacteria, retain memory and initiate a targeted 
prompt immune response (175).  
Immune responses seem calibrated to prevent S.pneumoniae colonisation and once established, its 
clearance. High levels of specific antibody in the mucosa lead to agglutination of bacteria, making it 
easier to be removed by mechanical mechanisms such as ciliary clearance (150). Anti-pneumococcal 
protein antibodies may help protect against colonisation, by opsonisation of bacteria (156). This 
forms part of the initial response preventing acquisition. Early degranulation of neutrophils is seen in 
nasal mucosa of non-colonised participants (176). 
Once established, immune mechanisms work to control and clear colonisation. IL-17 secreted by 
CD4+ T helper cells (Th17) recruits and activates neutrophils and macrophages and may help with 
clearance (165, 177). Increase in IL17 is observed with age and may explain reduced rates of 
colonisation (178). This may be due to the presence of memory Th17 cells secondary to past 
exposure. An inverse relationship between T regulatory cells and IL17 is seen with increasing age.  
Alveolar macrophages are closely adherent to alveolar epithelial cells and form an important part of 
immune response to S. pneumoniae. They are involved in phagocytosis of bacteria which leads to 
release of proinflammatory cytokines such as interferon g (IFN g), tissue necrosis factor β (TGFb), and 
recruitment of neutrophils and (179). Following nasopharyngeal colonisation, bacteria reach the 
lungs and are a stimulus for activation of alveolar macrophages. The binding of bacteria to alveolar 
macrophages leads to phagocytosis and formation of phagolysosomes leading to intracellular killing. 
This internalisation is enhanced in the presence of opsonising antibodies (180).  
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 Pneumococcal Vaccination in Asthma 
Guidelines for pneumococcal vaccination in asthma differ between adult and paediatric patient 
populations and this often creates confusion in clinical practice (181). Current United Kingdom 
guidelines recommend vaccinating patients with chronic respiratory disease including asthma using 
the PPV (2). The Centres for Disease Control and Prevention (CDC) recommends vaccination 
according to disease severity in adults, with PPV for mild asthma and PCV for severe disease 
(requiring high dose corticosteroids) (182).  
 Pneumococcal Vaccines 
Two types of vaccines are available: pneumococcal polysaccharide vaccine (PPV) and pneumococcal 
(polysaccharide) conjugate vaccine (PCV). 
PPV provides serotype specific immunity, targeting capsular polysaccharides and induces short term 
immune response by stimulating a subset of B cells producing IgG2 subclass antibodies (183, 184). 
PCVs comprise of a polysaccharide in conjunction with a protein, stimulate a T cell dependent 
serotype specific immune response, and stimulate memory B cells (185, 186). The 23-valent PPV 
vaccine has been available since 1983 and the 7-valent PCV (PCV-7) was licenced in the USA and 
Europe in 2000 and 2002 respectively (186) followed by 10- and 13-valent vaccines in 2009 and 2010 
respectively (187, 188). Serotype replacement by non-vaccine type strains has been observed after 
introduction of vaccination (16).  
 People with asthma have a blunted pneumococcal antibody response 
Children with asthma who have been recurrently exposed to bacteria such as S. pneumoniae are 
observed to have low antibody levels, including those with recurrent clinical infection (189). In a 
study by Rose and colleagues, putatively protective levels were seen in 20% and 54% of young 
children depending on serotype considered. Vaccination of these children with PCV was apparently 
more effective than PPV in raising antibody levels to putatively protective levels (189). A further 
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study by this group investigating sequential immunization with PCV then PPV showed around 80% 
children did not have an initial protective level of 0.35ul/ml (190). 
Similarly, a Korean study measured Ig levels to six serotypes (6B, 9V, 14, 18C, 19F and 23F) before 
and after vaccination in children aged 2-14 years. They studied healthy children and compared to 
those at clinical risk of invasive disease such as those with nephrotic syndrome, recurrent bronchitis 
due to asthma and post-splenectomy. The combined geometric mean (GM) for antibodies before 
and after vaccination with PPV were significantly lower in the high risk children compared to healthy 
(191). 
 It is uncertain if people with asthma are less likely to gain clinical benefit 
from pneumococcal vaccination 
A retrospective observational study examined pneumonia episodes in patients with asthma before 
and after pneumococcal vaccination, and compared these to age, gender and region matched 
controls who did not have underlying airways disease. This study included over 2700 patients with 
asthma and did not find a significant difference in rates of hospitalisation for pneumococcal 
pneumonia pre or post vaccination when compared with the control group (192). However, the 
patient population had a mean age of over 50 so was perhaps not typical of asthma patients, and the 
infrequent events gave rise to wide confidence intervals around estimates. 
Response to pneumococcal vaccination requires further investigation in asthma, as the bacteria has 
been identified in sputum and BAL samples in children and adults when stable and not experiencing 
an exacerbation (193-195). The response to pneumococcal vaccination in children with other allergic 
conditions appears lessened (196), and they may have an increased risk of invasive S. pneumoniae 
infection.  
The paucity of evidence around the clinical effect of vaccination on people with asthma suggests 
further research is needed. As a “real-world” trial is unlikely to happen given the size of the study 
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required, experimental challenge in humans is an appropriate alternative, due to expedience, lower 
cost and more controlled nature requiring fewer participants. 
 Broncho alveolar Lavage in Asthma  
Broncho alveolar lavage (BAL) sampling is used to study innate, cellular and humoral immune 
responses, determining cell population profiles that can facilitate the diagnosis of various diffuse 
lung diseases (180, 197-200).  
Bronchoalveolar lavage samples from mice previously colonised with pneumococcus have 
demonstrated an enhanced inflammatory response to lung infection, with an increased recruitment 
of neutrophils, higher levels of cytokines TNFa, IL6, IL22 and IL17 (201). Antibody levels have also 
been studied in BAL samples. 
In humans, bronchoalveolar lavage has been used in patients with pneumonia and experimentally 
colonised healthy controls to study mucosal immune response (180) (202). It is a useful investigation 
in asthma, helps to distinguish different phenotypes, and to study immune mechanisms in the lower 
respiratory tract (203-205). The safety is well established, and this can provide invaluable 
information on the alveolar response to pneumococcal colonisation in asthma with comparison to 
healthy controls. Research is ongoing to develop new techniques and tests for diagnosing asthma, 
with interest in understanding Particles in Exhaled Air (PExA Ó) and volatile organic compounds 
(VOCs) (206). PExA Ó combines breathing manoeuvres with sophistaicated analysis instrumentation 
to collect biological samples from small airways. Differences have been identified in the breath of 
those with and without asthma in preliminary investigations with further studies ongoing.  
Developing a safe and effective technique for people with asthma is important for future challenge 
studies to investigate the immune mechanisms in the lung. Preliminary work to establish an 
adequate sampling protocol is included in this thesis. However, subsequent sampling of challenged 
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asthma participants has not been undertaken. Table 2 describes the possible samples that can be 
obtained using bronchoalveolar lavage in people with asthma.  
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Table 2: Possible sampling methods and targets for diagnosis and management of asthma   
 FeNO Eosinophils Microbiome Inflammatory/ 
Immune cells 
Antibodies 
Venous Blood X Ö x Ö Ö 
Breath Ö X x x X 
Nasopharyngeal 
Samples (nasal wash 
and swabs) 
X Ö Ö Ö Ö 
Induced Sputum X Ö Ö Ö Ö 
Bronchoalveolar 
Lavage (BAL) 
X Ö Ö Ö Ö 
Bronchial Biopsies X Ö Ö Ö Ö 
 Summary 
Nasopharyngeal colonisation is the first step towards invasive pneumococcal disease (6), and 
inflammatory conditions lead to an increase in both the rate and density of S. pneumoniae (10). 
Damaged airway mucosa and use of ICS in asthma together may increase nasopharyngeal 
colonisation and its density leading to a higher risk of pneumonia in asthma (29).  
Antibodies against capsular polysaccharides are an important defence against S. pneumoniae, and 
low levels are seen at baseline with a reduced response after vaccination in asthma. There is little 
information about the impact and responses of PCV and PPV vaccination in clinical practice. 
There are cost implications in checking baseline antibody levels, and vaccinating everyone with 
asthma, particularly as effectiveness is uncertain. The antibody levels are only checked in patients 
who present with recurrent chest infections with asthma often requiring prolonged and multiple 
courses of antibiotics or in those who have radiological evidence of bronchiectasis (153). These 
patients are often referred and seen in tertiary severe asthma clinic for better characterisation of 
asthma phenotypes, as it may help in understanding the pattern of immune responses.  
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The immune mechanisms associated with nasopharyngeal colonisation and disease from S. 
pneumoniae, and the low immune responses at baseline and in response to vaccination require 
further investigation in asthma. In addition, pneumococcal virulence factors such as pneumolysin, 
which causes necroptosis of immune cells, may increase the risk of invasive disease and colonisation 
in asthma. Large prospective observational and vaccine intervention studies can address these gaps 
in our knowledge. These can be costly, time-consuming and challenging. Controlled human challenge 
models provide a more suitable option to study immune mechanisms in response to bacterial 
colonisation and eliminate the need to translate data from animal models into human trials whilst 
requiring a far smaller and more intensely studied cohort. Experimental human pneumococcal 
challenge (EHPC) has been shown to be well tolerated and informative in people without asthma 
(207). This type of approach could yield important pathological insight into the interaction between 
asthma, its treatment, and pneumococcus. 
  Experimental Human Pneumococcal Carriage Model 
(EHPC) 
An overview of the principles of EHPC model are presented in this section, the basic principles are 
similar for all the studies performed using the EHPC and here the asthma study is used as an 
example. 
Nasopharyngeal colonisation is the first step towards an infection with S. pneumoniae (6), and a 
source of immunity secondary to exposure (175). EHPC involves nasal inoculation with a strain of S. 
pneumoniae which elicits strong immune responses during colonisation and density levels close to 
those naturally detected with a low risk of causing invasive disease (175). There have been no cases 
of invasive pneumococcal disease to date in particpants of EHPC in Liverpool (208). Only one 
reported otitis media has been seen as an adverse event. It is reproducible and has been used safely 
since 2011 in Liverpool. It is well established to test efficacy for vaccines designed to reduce 
nasopharyngeal colonisation (152). The initial studies were done with healthy volunteers aged 18-50 
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years and now extended to study susceptible groups such as asthma, current smokers, patients with 
chronic obstructive pulmonary disease and healthy volunteers over the age of 50 years. A study 
looking at the effect of live attenuated influenza vaccine on colonisation has also been performed 
(209). Safety and ethical considerations are an essential part of any controlled human challenge 
model and require careful consideration. 
  Ethical considerations 
2.10.1.1  Autonomy 
Participation in the study was voluntary and it was ensured participants did not feel under pressure. 
All the participants were given written (Appendix A) and verbal information in simple, easy to 
understand language, enabling them to comprehend the purpose of the study, including any risks. 
The participant information sheet was sent at least twenty-four hours before consent to give time to 
read and consider the information. They were provided opportunity to ask questions individually 
before consent after an in-detail presentation. They could withdraw consent at any time if they 
wished, without providing any reason. Participants were compensated for their time and 
inconvenience. The payments were in keeping with the earlier EHPC studies and did not amount to a 
financial incentive. 
2.10.1.2  Beneficence 
Participants had relevant tests, examination and were offered information and education about 
their condition. There was an opportunity to ask questions and gain understanding of their medical 
condition by participating in clinical research. Control of asthma and severity was assessed during 
clinical screening and patients were investigated for any unexpected conditions identified as a result. 
2.10.1.3  Non-maleficence 
It was the responsibility of the research team to minimise the risk of harm to the participants. The 
research team had adequate knowledge and received appropriate training in accordance with 
current guidelines for the interventions and their potential risks. To ensure safety, study specific 
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inclusion and exclusion criteria were defined (see Table 5 and Table 6). Inoculation was performed in 
groups stratified by BTS treatment step, to ensure those on lower treatment were inoculated first. 
Experienced and trained staff performed all research procedures, including inoculation, 
venepuncture, nasal sampling and spirometry. 
The risk to society of transmission of pneumococcus from study subjects to the wider community 
was minimised by selecting participants who reported no regular contact with vulnerable 
populations (including children aged under 5 years see Table 6) and administering bactericidal 
antibiotics to all participants who remained colonised at the end of the study (bacterial culture 
positive from nasal wash at the last or penultimate visit). 
The specific risks to participants and their mitigation is discussed in section Safety considerations 
2.10.1.4  Justice 
This was balanced with non-maleficence. The research was open to all individuals, but important 
exclusion criteria were in place, primarily to protect individuals from undue risk.  
 Hypotheses 
I hypothesise in people with asthma:  
1. Experimental pneumococcal nasopharyngeal colonisation  
• is increased compared to healthy controls- A sample size of 52 was estimated from 
historic challenge study data in healthy volunteers (colonisation rate 49.6%) and 
assuming 50% reduction in colonisation rate in people with asthma (i.e. absolute risk 
difference 24.6%).  
• is of a shorter duration in asthma due to underlying inflammation – no prior 
literature from human data are available on this  
2. Clinical characteristics of the condition may affect experimental colonisation outcome 
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• High FeNO and eosinophil count due to increased airway inflammation may be 
associated with increased colonisation rates, for example secondary to increased 
bacterial  adherence sites and may also lead to rapid clearance secondary to 
mucosal immune activity both humoral and cell-based.   . 
• Disease severity as measured by low FEV1 and PEFR may affect colonisation 
outcome - secondary to uncontrolled airway inflammation or treatment such as 
high dose of ICS. 
• High ICS doses may be associated with increase in colonisation due to a reduced 
mucosal immune response secondary to their anti-inflammatory effect 
3. Systemic immune response to nasopharyngeal colonisation  
• May be reduced due to the condition itself, secondary to ICS therapy or a reduced 
duration leading to a shorter exposure of antigen. 
4. To establish a safe and effective sampling method for performing research BAL in asthma 
This may be used in be used in people with asthma to study mucosal immune responses 
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3 Methods 
 Introduction 
This chapter outlines the methodology used to set-up and perform the study, describes the process 
of study design, ethical issues, recruitment, implementation and study processes.  
  Experimental Human Pneumococcal Colonisation: Effect of Asthma on 
Immune Response to Pneumococcus 
The Experimental Human Pneumococcal Carriage (EHPC) model was used to study experimental 
colonisation rates and mucosal and systemic immune responses in participants with asthma. I 
prepared the study protocol, and lead the process of ethical and governance approvals, along with 
recruitment, reviewing participants to determine eligibility and the analysis of samples.  
This is a study of participants with mild to moderate well controlled, physician diagnosed asthma, 
aged 18-50 years, all on treatment with inhaled corticosteroids. They were inoculated with 
Streptococcus pneumoniae, serotype 6B, and were followed for four weeks to enable assessment of 
carriage acquisition and immune protection. The participants were at British Thoracic Society 
Treatment steps 2 and 3 according to the treatment prescribed. The BTS treatment steps are shown 
in Table 3 and discussed in detail in section 2.3.4 of chapter 2. All the participants were required to 
be on inhaled corticosteroid (ICS) up to a maximum dose of 800 micrograms (mcg) beclomethasone 
dipropionate (BDP) equivalent, conversion explained in Table 4. The risk categories were determined 
accordingly as described in Table 3, depending on the BTS treatment for asthma, higher risk 
individuals were postponed until 6 lower risk volunteers were inoculated, and safety demonstrated.  
 Ethical Approval  
This study was approved by the Liverpool East NHS Research Ethics Committee (reference number 
NW/016/0124, Integrated Research Application System (IRAS) ID - 199884, ISRCTN 16755478) and 
was co- sponsored by the Royal Liverpool University Hospital (Research Development and Innovation 
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(RD&I) Study number 5173) and the Liverpool School of Tropical Medicine (RD&I Study number 16-
010). The project was funded by MRC programme grant (MR/M011569/1).  
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Table 3: BTS Treatment steps and risk categorisation  





















Initial add-on therapy  Persistent poor-
control 
Continuous or frequent 






Inhaled short acting 








• Add in inhaled long acting 
β2 agonist (LABA) 
• Increase ICS up to 800mcg 
• Consider other therapies – 
Leukotriene receptor 
antagonists (LRA) and slow 
release theophylline  
SABA+LABA 
• Increase 









Risk Category  
 
 1 2   
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 Table 4 Inhaled Corticosteroid dose chart conversion 
Inhaled Corticosteroid, Device and Brand Equivalent Dose* 
These dosage equivalents are approximate and will depend on other factors 
such as inhaler technique. 
Beclomethasone 200mcg 
Clenil MDI 200mcg 
Dry powder inhalers; Easyhaler, Pulvinal, Asmabec 200mcg 
QVAR devices  100mcg 
Fostair MDI / Nexthaler (with LABA) 100mcg 
Budesonide 200mcg 
Easyhaler, Turbohaler, Symbicort (with LABA), Duoresp (with 
LABA) 
200mcg 
Fluticasone propionate 100mcg 
Flixotide Evohaler, Flutiform MDI (with LABA) Sirdupla MDI 
(with LABA) 
100mcg 
Fluticasone furoate   
RelvarÒ 1000mcg 
(*these values represent clinical equivalence only and are not similar pharmacologically) 
 Recruitment and selection 
 Study Promotion 
I recruited participants with physician diagnosed asthma at BTS treatment steps 2 and 3, by 
advertising on the University of Liverpool website, promotion on specific events such as fresher’s 
fair, Liverpool School of Tropical Medicine Open day and in the library. Advertisements inviting 
volunteers to participate were placed on physical notice boards in public areas within the hospital 
and university and on social media of these institutions.  
Primary care recruitment was done in collaboration with the National Institute of Health Research 
(NIHR), who approached all the practices within the Liverpool Clinical Commissioning Group, 
including some from the Wirral Commissioning Group. The practices were sent out a standard email 
with details of all the studies being supported by the NIHR. An ethically approved participant 
invitation letter was sent out to eligible patients from participating practices (Appendix B).  
Interested volunteers contacted the research team by phone or email for further information. The 
Royal Liverpool and Broadgreen University Hospital (RLBUHT) database (consent4consent) was also 
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used to approach potential participants. They were invited to discuss the study as a group and were 
given the opportunity to ask questions individually. Participants were given as much time as required 
to decide and consented once it was ensured they understand the study objectives, associated risks 
and potential benefits. Further clinical information was sought from their GP.  
 Recruitment:  
3.2.2.1  Inclusion criteria 
These are described in Table 5. 
Table 5: Inclusion Criteria  
General Inclusion Criteria: Rationale  
World Health Organisation performance status 0 (able to 
carry out all normal activity without restriction) or 1 
(restricted in strenuous activity but ambulatory and able to 
carry out light work) 
To reduce the risk of including 
participants with multiple other co-
morbidities  
Fluent spoken English  To ensure a comprehensive 
understanding of the research project 
and their proposed involvement 
Access to their own mobile telephone  For safety and timely communication 
 
Capacity to give informed consent 
 
Ethical requirement to ensure 
autonomy 
Specific Inclusion Criteria: 
 
Adults aged 18-50 years, with a diagnosis of asthma as 
described in Figure 9 
To include participants with mild 
asthma on preventive medication 
No exacerbations requiring antibiotics or oral steroids 
within the last 28 days 
To ensure safety and scientific 
integrity of results as steroids may 
affect the immune response and 
antibiotics can alter nasopharyngeal 
colonisation  
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Spirometry: Forced Expiratory Volume in one second >70% 
predicted 
To include only those with mild 
disease  
3.2.2.2  Exclusion criteria 
These are explained in Table 6. 
Table 6 : Exclusion Criteria  
 Exclusion Criteria Rationale 
1. 
 
Close physical contact with at-risk individuals (children 
under 5yrs, immunosuppressed adults) 
To reduce the risk of pneumococcal 
transmission in vulnerable groups 
2. History of drug or alcohol abuse - frequently drinking 
over the recommended alcohol intake limit: men and 
women more than 14 units of alcohol per week. 
Alcohol excess can lead to impaired 
immune response and may increase the 
risk of pneumococcal disease 
3. Current Smokers Smoking is an independent risk factor 
for pneumococcal disease 
4. Ex-smoker with a significant smoking history (>10 pack 
years – defined as someone smoking 20 cigarettes a day 
for 10 years) – minimise risk of pneumococcal disease 
(For loose tobacco: ounces per week × 2/7 × number of 
years smoked  =  pack years (210)) 
These participants might have 
obstructive airways disease other than 
asthma 
5. Taking medications that may affect the immune system 
e.g. oral steroids, steroid nasal spray, antibiotics, and 
disease-modifying anti-rheumatoid drugs.  
Such medication may affect immune 
responses 
6.  Any acute illness (new symptoms within preceding 14 
days which are unexplained by the known past medical 
history) 
 
This ensured participant’s safety as they 
may have had an underlying 
undiagnosed condition or could be 
suffering from an infection 
7.  Having received any antibiotics, oral steroids or nasal 
steroid spray in the preceding 28 days 
 
 
Antibiotic treatment may alter the 
normal nasopharyngeal flora and may 
affect primary outcome. Nasal steroids 
can alter the mucosal immunology. 
8. More than 1 asthma exacerbation in the last twelve 
months (Asthma exacerbation defined as an acute 
episode of progressive worsening of symptoms 
of asthma, including shortness of breath, wheezing, 
cough, and chest tightness, or a decline in objective 
measure such as peak expiratory flow rates of more than 
30 percent requiring treatment with oral corticosteroids 
for a period of 3 days or more) (211) 
This helped us include volunteers with 
well controlled disease, therefore 
ensured safety. 
9. Taking medication that affects blood clotting e.g. aspirin, 
clopidogrel, warfarin or other oral or injectable 
anticoagulants 
To avoid risk of excess bleeding post 
nasal cell sampling 
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10. History of culture-proven pneumococcal disease This ensured safety and scientifically 
they may have previous antibody 
response.  
11. Allergy to penicillin/amoxicillin Colonised participants were treated 
with amoxicillin at the end of the study. 
 
12. 
Currently involved in another clinical trial unless 
observational or in follow-up (non-interventional) phase. 
To avoid any interactions or adverse 
events due to other trial 
medication/intervention 
13. Have been involved in a clinical trial involving EHPC and 
bacterial inoculation in the past three years 
This may confer protection from 
previous exposure 
14. Significant cardiorespiratory disease (excluding stable 
hypertension, and asthma at treatment step 2 and 3) 
Respiratory disease may affect 
nasopharyngeal colonisation 
15. Disease associated with altered immunity, including 
diabetes, alcohol abuse, malignancy, rheumatological 
conditions 
These can impair immune responses  
16. Pregnancy For safety and due to immune changes 
in pregnancy 
17. Taking any medications except those on the “allowed 
list”:  
• statins;  
• anti-hypertensives;  
• antidepressants;  
• bisphosphonates;  
• hormone replacement therapy 
• vitamin supplements (including multivitamins, 
iron) 
• anti-acid medications 
• nicotine replacement therapy (NRT) 
•  inhaled steroids up to 800 micrograms BDP 
equivalent  per day 
• inhaled beta 2 agonists 
• leukotriene receptor antagonist 
These comprised of medications which 
do not cause significant alteration of 
immune function and ensured safety of 
our participants. 
 
Previous pneumococcal vaccination was not an exclusion criterion, as pneumococcal polysaccharide 
vaccination is currently recommended in asthma (as per The Green Book, accessible on 
https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25). Vaccine 
status of volunteers was recorded where available. 
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  Assessment for participation 
Assessment was completed in 2 stages -consent and pre-screening. Both are explained in detail 
below. 
  Consent 
This was done as explained in 3.2 
  Pre-screening 
After the completed General Practitioner Questionnaire (GPQ) (Appendix C) was received and no 
exclusion criteria were identified, participants were invited for the first appointment. At each visit 
consent was confirmed and their identification checked with previous obtained copy in the 
volunteer master file. The study nurse or doctor took a brief history to ensure the volunteer met all 
the screening criteria. This was followed by targeted clinical examination involving auscultation of 
the lungs and heart sounds, general observations and the participants were weighed and measured 
to perform spirometry with reversibility. The tests were done in the following order: Fractional 
Exhaled nitric oxide (FeNO), spirometry with reversibility, peak expiratory flow rates (PEFR) and 
bloods. FeNO was performed before spirometry, as the reading can be altered if measured after. All 
the procedures were performed according to the standard operating procedure and these are 
described in detail below. Any abnormality identified was explained to the participant, and all 
relevant results were forwarded to their GP to arrange appropriate investigations and follow-up as 
required. The GPs also received copy of spirometry results for all the participants. 
3.2.5.1  Asthma Action Plan 
This is usually done in primary care by the nurses for all patients with asthma. This was completed by 
a member of the research team for participants who did not have one. Only 4 of the particpants had 
an asthma action plan from primary care at the time of enrolment into the study.  The plan 
supported by Asthma UK was used (212) see Appendix D.  Further participation was determined 
according to the stop criteria in Table 7. Eligible participants were asked to maintain a PEFR diary 
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(Appendix E) and further appointments booked. Final confirmation was sent when the results of the 
blood tests were available.  
 
 
Table 7: Baseline assessment and Stop criteria 
 Stop criteria 
Age STOP if <18 or >50 years  
Clinical history + examination STOP if unexplained or concerning findings on 
history or examination 
Engagement with research team STOP if the research team have concerns about 
volunteer’s ability to commit to frequent 
communication + safety checks 
Full blood count (FBC) STOP if Haemoglobin (Hb)<10g/l 
STOP if total White Cell Count (WCC) <1.5 x109/l 
or neutrophils <1.0 x109/l 
STOP if total WCC >10 x109/l 
STOP if platelets <75 x109/l 
Resting SpO2 STOP if < 95% 
Spirometry STOP if FEV1 < 70% 
PEFR  <75% of predicted  
BTS Treatment Step <2 or > 4  
An interim safety report was sent to the Data Safety and Monitoring Board (DSMB) after 6 participants 
on step 2 were completed. Safety was defined as per previous EHPC studies: ≥6 uneventful completed 
participants per group and no reservations among the clinical team and data monitoring and safety 
committee about proceeding.  
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Figure 3: Asthma Diagnostic Tests- Protocol V 1-4 
This flow chart explains the inclusion criteria for participants up to protocol version 4 – where an 
objective evidence for the diagnosis of asthma in the form of FEV1 reversibility post salbutamol, FeNO 
>40ppb or documented evidence of these by the GP was sought. If neither were present participants 
were placed in a waiting group pending further tests 
 
3.2.5.2 Tests to confirm diagnosis of asthma: 
These were performed on the pre-screen appointment (up to 7 days before collecting nasal and 
blood samples on the screen visit). 
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3.2.5.2.1  Fractional Exhaled Nitric Oxide (FeNO) 
This was measured using Niox Vero® Figure 4 and involved blowing into the machine at a steady rate. 
FeNO measures airway inflammation and is routinely used for diagnosis and monitoring of asthma in 
clinical practice. The measurements are recorded in parts per billion (ppb) (213) Table 8 and is very 
sensitive with several substances altering the result (50, 214) as described in Table 9. 
 
 Table 8: Interpretation of FeNO Values  
FeNO levels and inflammation 
FeNO (ppb) Normal Elevated High 
Adults  <20-25 20/25-50 >50 
Th2 driven Inflammation Unlikely Likely Significant 
 
Table 9: Factors Disturbing FeNO Measurement  
Factor Increasing FeNO measurements  Factors Reducing FeNO Measurements 
Age/Gender-levels increase with age in children Respiratory Manoeuvres 
Airway calibre - variable with degree of 
obstruction 
Reduced after alcohol ingestion 
Ingestion of nitrate or nitrate containing-foods 
such as lettuce 
Smoking - but increased in smokers with 
asthma 
drinking water Oral and Inhaled corticosteroids 
Caffeine NO synthase inhibitors 
Respiratory tract infection Leukotriene receptor antagonists 
 Hypoxia 
 
FeNO was measured before spirometry and PEFR. The machine was set up in advance and a new filter 
placed. Participants were explained to breathe out completely, then form a seal around the mouth 
piece as shown in Figure 4, and breath in until the machine indicated. Then they had to breathe out 
at a steady rate for at least 10 seconds. Only adequately performed tests were accepted and a result 
generated.   
  
Methods – Effect of Asthma on Immune Response to Pneumococcus
  Page 60 
 
Figure 4 Niox Vero®  
 A participant performing the FeNO test using Niox Vero® (consent was sought for taking pictures to 
use for the thesis and study promotion) 
3.2.5.2.2 Spirometry with reversibility 
This was measured using the EasyOne® Plus Diagnostic Spirometer Figure 5, and following 
parameters were recorded: 
A. Forced Vital Capacity (FVC) is the total volume of air exhaled in a forced expiratory 
manoeuvre. 
B. Forced Expiratory Volume at One Second (FEV1) is the amount of air blown 
out during the first second of a forced expiratory manoeuvre.  
C. The ratio of FEV1 to the FVC (FEV1/FVC) is the most sensitive and specific index of 
airways obstruction measured by a spirometer. It is obtained by dividing the FEV1 by the FVC, 
and is usually expressed as a percent (i.e., 100 x FEV1/FVC). 
3.2.5.2.3  Medications prior to testing 
Participants were asked to withhold their inhaled medication both short and long acting prior to 
attending the clinic for the test and any bronchodilator medications taken during the 24 hours prior 
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to the test were recorded. Medication used prior to testing can influence the pre-bronchodilator 
measurement Table 10. 
 
Table 10: Medication examples and duration to withhold prior to test 
Types of Medication  Examples Withhold Prior to Test 
Short Acting Beta Agonist Salbutamol, Bricanyl 6 hours prior to clinic visit 
Long acting Beta 2 Agonist Formoterol, Serevent,  12 hours prior to clinic visit 




3.2.5.2.4  Contraindications for spirometry testing 
In addition to the exclusion criteria for this study, following conditions were considered before 
performing the test. 
• chest or abdominal surgery in the past three months 
• a cardiac event in the preceding three months 
• detached retina or eye surgery in the past three months 
• hospitalization for any other heart problem in the past month 
• a resting pulse rate more than 120 beats/minute measured at least 5 minutes after sitting 
down. 
3.2.5.2.5  Performing the test  
Participant details were entered in the spirometer and this was connected to a laptop with software 
pre-installed to enable reading the results. A mouth piece (spirette) was attached and the 
manoeuvre explained. The participants were asked to take a deep breath in and blow into the 
spirometer as hard and fast as possible, until their lungs were completely empty. This routine was 
repeated 3 times to ensure the results were consistent, then they were given 400 mcg salbutamol 
inhalers with an aero chamber spacer and the test was repeated 15-20 minutes later to determine 
Methods – Effect of Asthma on Immune Response to Pneumococcus
  Page 62 
reversibility. This test forms part of standard asthma care (215). American Thoracic Society (ATS) 
criteria were used for quality assurance (70). 
 
Figure 5: EasyOne® Plus Diagnostic- the device used for measuring spirometry during the study 
 
3.2.5.2.6  Peak Expiratory Flow Rates (PEFR): 
PEFR is a measure of the fastest rate of air (airflow) blown out. It was measured using a Mini 
Wrights® peak flow meter in litres per minute (L/min) Figure 6. Participants were shown how to take 
a peak flow reading (i, put the marker to zero, ii, take a deep breath, iii, seal lips around the 
mouthpiece, and blow as hard and as fast as possible into the PEFR meter). They were asked to 
perform three readings and record them on the chart provided to maintain a diary (Appendix E) 
from this visit onwards. The PEFR variability was calculated by using a tool developed in house with 
Microsoft Excel (Appendix F). A PEFR variability of 12 percent was accepted for this study. 
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Figure 6: Mini Wright’s Peak Expiratory Flow Rate Meter 
 
 Subjects and timelines 
Participants aged 18-50 years with asthma were inoculated with pure culture of a well-characterised, 
fully sequenced penicillin-sensitive pneumococcal serotype 6B (strain BHN418). They were observed 
for the development of pneumococcal colonisation.  
Study visits took place within 7 days of the proposed date to accommodate for issues/events and 
personal commitments of participants that prevented them from attending (e.g. illness, 
bereavement, exams, professional and travel issues) Figure 7. The samples collected at each time 
point are described in the text and in Table 11. 
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Figure 7 Study Visits – Flow chart detailing study visits and time points 
 General Practice Questionnaire (GPQ), Peak Expiratory Flow Rate (PEFR), Fractional Exhaled Nitric 
Oxide (FeNO), Asthma Control Test (ACT), Day (D), Three times per day (TDS)  








•Medical history, clinical examination 
•PEFR diary, FeNO, Spirometry with reversibility, blood
Screen 
Visit
•Vital Observations, PEFR diary, ACT Score
•Nasal and blood samples as explained in table 11
D0
•Inoculation, PEFR diary, Symptoms log
•Samples as explained in table 11
D2
•PEFR Diary, Symptoms log
•Samples as explained in table 11
D7
•PEFR Diary, Symptoms log, FeNO
•Samples as explained in table 11
D9
•PEFR Diary
•Samples as explained in table  11
D14
•PEFR Diary
•Samples as explained in table 11
*D22
•PEFR Diary
•Samples as explained in table 11
D29
•PEFR Diary, ACT score
•Samples as explained in table 11
Methods – Effect of Asthma on Immune Response to Pneumococcus
  Page 65 
  Visit 1: Pre-Inoculation screening visit 
The consent and eligibility were checked, and all the participants were asked to complete the 
Asthma Control Test questionnaire.  
3.3.1.1  Asthma Control Test (ACT) 
This is a simple questionnaire, designed to assess patients’ symptoms of asthma. A score of 25 
indicates good and that of less than 20 poor control. This is used as part of standard asthma care in 
secondary care (216) (Appendix G). I was unable to use Asthma Control Questionnaire (ACQ) score 
as this is copyrighted and would have rquired permission before use. However, both ACT and ACQ 
scores are validated and widely used in clinical practice to asses asthma control which was the 
purpose of administering the test in my study (217).  
3.3.1.2 Pregnancy Test 
A urine β HCG test was performed on all female participants. 
3.3.1.3 Throat swab 
The participant’s tongue was depressed using a tongue depressor exposing the palatopharyngeal 
arch. Two samples were obtained: one for bacterial identification (blood agar), and one for detection 
of pathogens by molecular techniques, each by making 5 small circular motions of the 
palatopharyngeal arch in contact with the mucosa whilst avoiding the tongue. Throat swabs were 
collected prior to nasal wash to ensure the oropharynx was not contaminated with nasal pathogens.  
3.3.1.4  Nasal Samples 
3.3.1.4.1  Nasal wash 
This was performed using a modified Naclerio method (218). This has been used for more than 8 
years for pneumococcal carriage studies, is a sensitive method for bacterial detection and 
quantification, being more comfortable than nasal swabs for participants (219). Five millilitres of 
saline were introduced using a syringe and held for a few seconds in the nose before being expelled 
into a sterile container. This was repeated twice in each nostril using 20ml saline in total. In the 
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event of nasal wash loss (defined as cough/sneeze/swallow) the procedure was repeated to obtain 
an adequate specimen (defined as ≥10ml saline recaptured). The sample was transported to and 
processed at the laboratory in Liverpool School of Tropical Medicine within 60 minutes of collection. 
If more than 20ml of saline was used, this was documented on the form for information of the 
laboratory team. The sample was then spread onto agar plates as described below in section 3.5.2 to 
determine nasopharyngeal colonisation of bacteria. 
3.3.1.4.2  Rhino probes 
Nasal cells were collected using a naso-sampling method where cells are obtained through 
minimally-invasive superficial nasal scrape biopsies (Rhino-pro nasal curette) with no significant side 
effects (220). Up to 4 samples were obtained at each nasal sampling visit. These were used to obtain 
a higher density of cells from the mucosa and submucosa compared to that achieved with nasal 
wash. 
3.3.1.5 Blood 
Up to 50mL of blood was collected by venepuncture to measure full blood count (for safety), and 
immune responses such as serum immunoglobulins. The serum samples were stored for each 
participant at -80˚C, in 4 separate aliquots. 
 Visit 2 – S. pneumoniae Inoculation (D0) 
After identification and safety check (including PEFR diary), nasosorption samples were collected 
from participants. 
3.3.2.1 Nasosorption 
Concentrated nasal lining fluid was obtained for cytokine analysis using nasosorption strips (like 
blotting paper) developed by Hunt Developments Ltd (UK). Strips were held inside the nose for 1—3 
minutes then stored at -80oC pending cytokine analysis.  
3.3.2.2 Safety instructions prior to nasal bacterial inoculation  
Following this all the participants:  
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• were shown how to use the thermometer and record their temperature.  
•  given an emergency pack containing:  
1. a 3 day course of oral antibiotics (amoxicillin),  
2. a safety information sheet (Appendix H),  
3. symptom log (Appendix I)  
4. a participant study card with details of the study participant number (Appendix J), 
date of inoculation, the clinical team contact number and a new PEFR diary 
• Participants were explained and shown how to complete the symptom log for the next 7 
days and the day 0 was done in clinic prior to inoculation.  
• Contact numbers for the participants and a close friend (secondary contact) who was likely 
to see them every day (e.g. flat mate) were saved in the emergency study phone. They were 
all sent a text message from this study phone to ensure they had our number saved in their 
phones.  
• Instructions were given to record their temperature and three readings of PEFR and send 
these daily via text message before 12 noon to the research team. All the participants were 
asked to set a reminder in their phones.  
• They were explained the pack contained 9 capsules of amoxicillin and the reasons when they 
may have to be taken were explained as below: 
1. At the end of the study - if they were still colonised with the bacteria (unless they 
had two negative nasal washes) 
2. If they were unwell during the study and the research team asked them to take 
these. 
3. If they had any of the symptoms explained on the safety sheet and were unable to 
contact the research team, a GP or any other emergency department. Study team 
members were on call 24 hours a day seven day a week. 
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3.3.2.3  Inoculum Preparation 
The inoculum was prepared in the laboratory at the Liverpool School of Tropical Medicine, within a 
dedicated safety cabinet. Bacterial stock purity and penicillin sensitivity was confirmed by Public 
Health England laboratories. Frozen aliquots of S. pneumoniae were thawed and checked for 
bacterial number (colony forming units [CFU] per ml), and purity. Two identical tubes were 
prepared, one for inoculation and a second as a backup. The inoculum was immediately transferred 
to the clinical research unit and participants were inoculated with 80,000 CFU/100µl serotype 6B 
pneumococci administered to each nostril as explained below. 
3.3.2.4  Inoculation 
Participants were asked to lie down at a 45-degree angle in an adjustable chair. They were advised 
not to wipe their nose and remain in this position for 15 minutes after the inoculation. Using a P200 
micropipette 0.1ml saline containing the desired dose of S. pneumoniae was instilled into the nose. 
The target dose was 80000 CFU/100µl, with an allowable margin of error of half or double of this 
dose based on our dose-ranging studies with similar colonisation and safety outcomes (rates and 
density recovered from the nasopharynx) (221).  
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Pre-screen FBC      Spirometry 
PEFR meter to be given, FeNO 
Screen     ✓     ✓      ✓     ✓ ACT score 
Pregnancy Test 
D0          ✓   PEFR, Symptom log 
D2    ✓    ✓        ✓    ✓    ✓ PEFR 
D7    ✓    ✓        ✓    ✓    ✓ PEFR 
FeNO  
D9    ✓    ✓        ✓    ✓    ✓ PEFR 
D14    ✓    ✓     ✓     PEFR 
(D22) +    ✓    ✓     ✓     PEFR 
D29    ✓    ✓        ✓    ✓    ✓ PEFR 
ACT score 
*Throat swabs were collected for viral and bacterial culture on the screen visit, both were stored on ice immediately, and bacterial was 
transferred to the laboratory within 40 minutes of collection. Nasal Wash was collected at all timepoints except on the day of inoculation 
and was transported to the laboratory for processing within 40 minutes of collection, Nasal Cells were collected on screen visit, days 2, 7, 9 
and 29. Nasosorption was collected on days 0, 2, 7, 9 and 29. Peak Expiratory Flow Rate (PEFR), Fractional Exhaled Nitric Oxide (FeNO), 
Asthma Control Test (ACT). + Carriage positive participants only  
 
  Monitoring of participants and colonisation 
Colonisation was determined by bacterial culture of nasal washes. Participants were provided a clear 
flow chart of the necessary intervention should any symptoms develop ( Appendix H participant 
inoculation information sheet). A three-day course of amoxicillin, a digital thermometer and a PEFR 
meter were provided and participants asked to send text messages daily for the first seven days with 
their temperature and three PEF rate readings. These were recorded by a member of the research 
team. If they did not text by the specified time, a member of the research team contacted the 
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participant. If no response was received the prior defined ‘secondary contact’ was phoned. 
Participants had access to the research team 24/7 on-call telephone service until the end of the 
study after inoculation. 
 Study Amendments 
The protocol described above was the original submission to the ethics committee on the 3rd 
February 2016. However, during the study due to practical implications several amendments were 
made. These were submitted to REC using the IRAS system, and were approved by the committee, 
the Health Regulatory Authority and the sponsor before implementation. These are detailed in Table 
12, and substantial amendment 2 is discussed in detail as this changed the eligibility criteria 
significantly. 
  Substantial Amendment 2 
This amendment was submitted after discussion with the principal investigator (PI) due to difficulties 
with recruitment. The reasons and changes are explained below:  
1. Inclusion criteria changed from an objective diagnosis of asthma to physician diagnosed asthma. 
The reasons for this were:  
• We were looking for participants with mild well controlled asthma on low dose ICS at British 
Thoracic Society treatment steps two and three. These participants as per the BTS guidelines 
were on appropriate treatment to be symptom free. Therefore, the participants may not 
always have the features of airway inflammation required as per current diagnostic tests if 
well controlled.  
• This change enabled us to recruit participants with a physician diagnosis of asthma, on 
regular treatment with ICS based on historic symptoms. 
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2. I removed histamine challenge test from the diagnostic pathway, as with a change in inclusion 
criteria this was not necessary. The patient information sheet and protocol were amended 
accordingly. 
3. I included a reminder letter to the participants through the GPs, to increase response rate 
Appendix K. 
 4. An approved text for advertising our study on social media was added, to improve the publicity 
and advertisement of the study.  
Following approval of this amendment our study recruitment improved significantly and all those 
participants who were pre-screened and awaiting a histamine challenge test were included.  
Table 12: Study Amendments 
Amendment Type  Date Document Versions  Changes 







Website text V1 
Co-sponsorship 
Added a nasosorption test at day 29 
Text for website approved 
Study approval for co-sponsorship  
Minor amendment 2 10th May 
2016 
GPQ V2 GPQ changed to add “please provide a 
relevant summary or fill in the form” 
 previous records of past 12 months asked for 
instead of 3 years 
Minor Amendment 3  22nd June 
2016 
Protocol V5 Diagnostic flow chart simplified to help 





Protocol V7 Eligibility criteria changed from objective 
evidence to physician diagnosis a 
histamine challenge test removed (Figure 9 for 
eligibility criteria changes and Figure 10 for 
study visit 
Reminder letter from GPs added 
 social media statement 











Figure 8: Asthma Diagnostic Tests – Minor Amendment 3 Protocol Version 5  
Flow chart explaining inclusion criteria for asthma diagnostic tests  
  
                                                                Asthma Diagnostic tests:                                                                                                             
•  Spirometry with reversibility 
•  PEFR variability 
•  FeNO 
•  GPQ: Objective Evidence from any of the above tests 
Exclude:  
FEV1 <70% post 
bronchodilator 
Waiting group: 
• All the tests negative 
• Histamine challenge 
Include: 
• Reversibility >200mls or 
12% change 
• FeNO >40ppb 
• PEFR variability 
• GPQ evidence 
Waiting group: 
• All the tests negative 
• Histamine challenge 
test 













Figure 9 Asthma Diagnostic Tests – Substantial Amendment 2 Protocol Version 7 
Flow chart explaining inclusion criteria for asthma diagnostic tests following Substantial Amendment 2, these are further explained in Table 12 
                                                                      Asthma Diagnostic tests:                                                                                                             
•  Spirometry with reversibility 
•  PEFR variability 
•  FeNO 
•  GPQ: Objective Evidence from any of the above tests 
Exclude:  
FEV1 <70% post 
bronchodilator 
Include: 
• Physician diagnosed asthma on treatment and 
BTS step 2 and 3 
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 Laboratory Methods: S. pneumoniae Inoculation  
  Preparation of bacteria for inoculation 
As explained in section 3.3.2.3 the inoculation section 
  Nasal Wash Processing and determination of colonisation  
Colonisation was defined by the result of nasal washes taken at days 2, 7, 9, 14, 22 and 29 post inoculation. 
The colonisation status was determined by classical microbiology, as described below: Nasal washes were 
plated on culture media (blood agar plates with and without gentamicin) and incubated overnight at 37°C 
in 5% carbon dioxide (CO2). Colonies were confirmed as S. pneumoniae using classical microbiological 
techniques including (i) typical draughtsman-like colony morphology for gram-positive diplococci ii) the 
presence of α-haemolysis, (iii) optochin sensitivity, and (iv) solubility in bile salts. Typing by latex 
agglutination was done using a commercial kit to confirm pneumococcal serogroup. Isolates were frozen at 
-80ºC for storage.   
3.5.2.1 Materials and Reagents Required 
• Blood plates – Oxoid PB0122A  
• Skim milk, tryptone, glucose, glycerine (STGG) medium  
• Saline  
• Pipettes  
• 96 well plate – for dilutions  
• Eppendorf tubes  
• Cryotubes  
• Heraeus Megafuge 1.0 in the Microbiology lab CT350 
• Latex agglutination Kit 
• Gentamicin 1mg/mL 
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3.5.2.2  Preparation of STGG medium used for nasal wash pellet dilution and storage:  
3.5.2.2.1 Materials:  
• Oxoid tryptone-soya broth (CM 129) 3.0ml 
• Glucose 0.5g 
• Oxoid skim milk powder (CM L31) 2.0g 
• Glycerol 10.0ml 
• Double distilled water 100 ml 
Method: 1ml of each of the above materials were added into bijoux’s and autoclaved for no more than 10 
minutes. The tubes were stored at 4-6°C. The pellet was re-suspended vortexing for 10 to 15 seconds.  
3.5.2.2.2  Preparation of Plates 
Two different types of plates were required: Gentamicin plates, and dilution plates. Blood agar plates were 
purchased from Oxoid and labelled with volunteer ID, and study day. On the day of sample collection, the 
dilution plates were placed under a sterile hood and left to dry out.  
3.5.2.2.3  Gentamicin Plates:  
80µL of 1mg/mL gentamicin was plated on a blood plate and spread until dry. These were stored in the 
fridge until use.  
3.5.2.2.4  Dilution plates:  
These were blood agar plates, divided into four sections and labelled as below. 2 plates were made for each 
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3.5.2.2.5  Sample Processing:  
• The nasal wash was collected within one hour from the clinical research unit, and centrifuged for 10 
minutes at 4000 rpm, to separate the supernatant and the pellet 
• The volume of nasal wash was recorded on the inventory form  
• 1ml aliquots of the supernatant was transferred into each of 5-11 pre-labelled supernatant tubes 
(subject to volume collected from the participant) 
• 100µl of STGG was added to the pellet, and this was pipetted up and down 
• The volume of STGG in the tube was determined and recorded on the inventory form (usually 
>100µl) 
3.5.2.2.6  For Gentamicin Plates 
• 20µl was plated onto the blood agar with gentamicin (4µg/mL) and streaked  
• A 96 well plate was prepared for Miles and Misra (serial dilution) by adding 90µl of sterile saline 
into wells to 4 (or 8) wells 
• Then 10µl of the STGG pellet was added into well A and mixed by pipetting up and down 
• Serial 4 (or 8) 1:10 dilutions of the STGG pellet were made by starting to mix contents of well A 3-5x 
and transferring 10µl to well B. The top was changed, and process repeated using contents of wells 
B-C (or B-G) to reach well D (or H) 
• One 10µl drop from each well was placed into the corresponding section on the plate: Well A = 
section 1, Well B = section 2, well C = section 3, well D = section 4, well E = section 5, well F = 
section 6, well G = section 7, well H = section 8. This was repeated twice and a total of 3 drops were 
added to each section. 
• The sample was left to dry with the lid closed 
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3.5.2.2.7 For Blood Agar-dilution plates 
• 800µl of STGG was added to the nasal wash sample, and pipetted up and down  
• 25µl was plated on blood agar and streaked  
• The remaining amount of the cell pellet was divided into 3 labelled cryovials for collaborators for other 
experiments 
• The plates were incubated at 37°C for 9 to 16 hours in 5% CO2  
• The temperature and CO2 level were checked the following morning and recorded on the form  
• The plates were then examined the next day for presence of pneumococcus 
• If pneumococcus was detected, the colonies were counted on all the plates by two research assistants 
(blinded for each other’s count): 
Dilution Dilution 
Factor 
# of visible 
colonies 
CFU/100μl 
1 10   
2 100   
3 1000   
4 10000   
 
• The colonies were streaked for purity and frozen the next day to be stored at -80°C 
• The pneumococcus serotype was tested using the latex agglutination kit Oxford Biosystems, 
United Kingdom, as per manufacturer’s instructions. 
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  ELISA protocol to measure anti-capsular polysaccharide antibodies (CPS) 
antibodies 
These were all performed by myself in the LSTM laboratory with guidance from my laboratory scientist 
colleagues. I performed these tests using the protocol below over a 2 week period. 
3.5.3.1 Materials required 
• 96 well immuno sorp plates - Nunc Maxi®  
• 96 well deep well plate - Star Lab® 
• Purified 6B polysaccharide and cell wall polysaccharide (CWPS) - Oxford Biosystems 
• WHO international pneumococcal reference standard 89SF – supplied by Food and Drug 
Administration (FDA), United States 
• Goat anti-human IgG conjugated to alkaline phosphatase (secondary Ab): - Sigma Aldrich, St 
Louis, Missouri, USA 
• Phosphate Buffered Saline tablets (PBS)  
• Dilution Buffer: 2ml Heat-Inactivated foetal bovine serum (HI-FBS) in 20ml PBS 
• Absorption Buffer: 10µl CWPS (stock 10mg/ml) in 10ml of dilution buffer (final concentration 
10µg/ml) 
• Polooxyethylenesorbitan (Tween 20) - Sigma-Aldrich 
• Washing Buffer: 500µl Tween20 in 1L PBS 
• 1 tablet of p-nitrophenylphosphate (pNPP) (5mg) and 40ml of distilled water 
3.5.3.2 Method 
1. Each ELISA well of the Nunc Maxi® immuno sorp plate was coated overnight with 100 microlitre 6B 
polysaccharide (10µl of purified polysaccharide (stock 5mg/ml) in 10ml PBS – final concentration 
5µg/ml) and incubated at 4° C. 
 
Methods – Effect of Asthma on Immune Response to Pneumococcus Page 79 
2. Following morning, in a separate star lab® deep 96 well plate, standard was prepared in columns 1 
and 2 (wells A-H) using absorption buffer and 89SF in a dilution of 1 in 500). The samples were 
prepared in a 1 in 100 dilutions in rows A3 to A12 and E3 to E10. Each sample was put in two wells 
simultaneously for duplicates. 597 µl of absorption buffer with 3 µl of the sample was added to 
each well. Samples from different time points (day -5, day 7 and day 29) were all processed on the 
same plate. The plates were incubated for 30 minutes. The blank was prepared separately in wells 
H11 and H12 with 200 microliters of absorption buffer. 
3. The Nunc Maxi® plates which had been incubated overnight were washed 3-times with the washing 
buffer (PBS with tween) washed. 100 µl of the pre-absorbed standard serum was transferred from 
star lab® deep well plate to columns 1 and 2 (A-H) to the washed Nunc Maxi® plate. Similarly, 200 
µl of the samples were transferred to row A3 - A12 and E3-E10. 100 µl of dilution buffer were 
added to the remaining wells (B3-D13, and F3 to H10). Then 100 µl of the sample were transferred 
from A to B, mixed then from B to C and C to D, the tips on the pipetted were changed with each 
dilution. From row D 100 µl was discarded, leaving each well with 100 µl of sample. This process 
was repeated for rows E to H. The plates were incubated at room temperature for 2 hours. 
4. The plates were then washed 3-times with the washing buffer and 100 µl of secondary antibody 
was added to each well and incubated for 1 hour and 30 minutes. 
5. After washing the plates 3-times with the washing buffer 100 µl of pNPP (prepared by adding one 
tablet to 40 ml of distilled water) was added to each well. The plates were developed for ten 
minutes in the dark and read using the Omega software® ELISA reader at 405nm. 
6. Samples with coefficient of variation>15% between duplicates were repeated and one sample due 
to a very high signal (outside standard curve) was repeated using a 1 in 800 dilutions. 
 Meso Scale Discovery (MSD) for anti-pneumococcal protein antibodies 
This was performed at the WHO reference laboratory at the Institute of Child Health, University College 
London (Prof David Goldblatt).  
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3.5.4.1  Materials Required:  
• MULTI-SPOT® 96 10- Spot High Binding plates. Customised order from Meso Scale Discovery, 
Gaithersburg, MD 
• 96-well Microplate imager - MSD Sector Imager, Model #1300, MSD, Gaithersburg, MD 
• MSD Discovery Workbench 4.0.12 
• Deep well plate, 96 well 1.2 ml - Anachem 
• Pneumococcal Capsular Polysaccharide (CPS)- American Type Culture Collection (ATCC) 
• Pneumococcal Cell Wall Polysaccharide CWPS- Statens Serum Institute 
• Pneumococcal Proteins – 27 measured named below 
CbpA PP01 SP0609 PP31 PcpA PP13 RrgA-T4 PP22 Ply PP17 
LytC PP02 SP2027 PP07 PhtD PP14 RrgB-6B PP19 PspA F1 PP16 
PcsB PP06 SP2194 PP30 PhtE PP10 WtPly PP12 RrgB-23F PP20 
PhtD PP03 StkP PP05 PiuA PP08 NanA PP33 RrgB-T4 PP18 
PsaA PP04 LytB PP11 PspA F2 PP15 PiaA PP09 Spr0057 PP29 
Spr0096 PP24 Spr2021 PP32 
 
• WHO international pneumococcal reference standard 007sp - supplied by Food and Drug 
Administration (FDA), United States 
• Southern Biotech Goat Anti Human IgG – purified -  
• MSD SULFO -TAG NHS-ESTER 
• Human control sera in house control sera 96/570 - National Institute of Biological Standards and 
Controls (NIBSC) 
• Polooxyethylenesorbitan (Tween 20) - Sigma-Aldrich 
• Sterile non-pyrogenic water – Baxter Healthcare  
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• Phosphate Buffered Saline tablets (PBS) 
• Bovine serum albumin (BSA) - Sigma 
• Read Buffer T with surfactant (4X to 1X in sterile water) 
• Blocking Solution (5% Bovine Serum Albumin (BSA) in 1XPBS- 2.5g BSA in 50 ml PBS) 
• Antibody Buffer (DAB) – 1% BSA in wash buffer (1X PBS in 0.05% Tween) with CWPS (10ug/ml) with 
22F (5ug/ml) 
3.5.4.2  Method 
1. The plates were coated with proteins by MSD according to pre-defined specific requirements and 
stored at 4°C 
2. Standard was prepared using 007sp in a 1:100 dilution and a fourfold serial dilution was performed 
3. The samples were prepared in 1:100 dilution using DAB and added to the dilution block containing 
the reference standard in replicate 
4. Separately, two dilutions were prepared for the quality control (QC) sera – Low 1:1000 and high 
1:2000. These were added to the dilution block containing the reference standard and samples in 
replicate according to plate layout 1 (example shown below):  
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
B Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 
C Sample 11 Sample 12 Sample 13 Sample 14 Sample 15 
D Sample 16 Sample 17 Sample 18 Sample 19 Sample 20 
E Sample 21 Sample 22 Sample 23 Sample 24 Sample 25 
F Sample 26 Sample 27 Sample 28 Sample 29 Sample 30 
G Sample 31 Sample 32 Sample 33 Sample 34 Sample 35 
       
H BLANK Sample 36 Sample 37 Sample 38 Hi QC Lo QC 
 
5. Then 150 µl of the blocking solution was added to each well, sealed and incubated while shaking at 
700rpm for 1 hour at room temperature 
6. The plates were washed 4-times. 30 µl of detection antibody was added to each well, sealed and 
incubated at room temperature for 1 hour on the shaker as before 
7. The plates were washed and 150 µl of diluted read buffer was added to each well 
8. The plates were read immediately after 
 Safety considerations 
Safety of the participants and of the researchers was taken into consideration while planning the study. S. 
pneumoniae can cause infections such as otitis media (OM), sinusitis, pneumonia, bacteraemia and 
meningitis.  
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 Study design:  
Participants were provided with detailed information of the study before consent and information was 
given about their condition. A personal asthma action plan was completed based on peak expiratory flow 
rate (PEFR) readings explaining how to increase their inhaled medication and whom to contact if PEFR 
dropped. A daily PEFR diary was maintained by participants and checked at each visit by the study team. 
There was a process in place to ensure daily contact with the participants for the first 7 days including 
weekends.  
 Clinical on call cover  
A member of research team was on call 24 hours, seven days a week and was contactable via phone. The 
contact details were provided to the participants on a business card and they were advised to store these in 
their phones. The hospital switch board also had details of the on-call team. 
 Participant Selection:  
The inclusion and exclusion criteria as described in Table 5 and Table 6, were determined by experienced 
chest physicians with specialist interest in asthma, to ensure only those with mild, well controlled disease 
were included. Participants on BTS treatment step two with mild disease were inoculated first and after 
successful completion of six participants, those on step 3 were included. Table 3 explains the BTS treatment 
steps and risk categorisation.  
 Laboratory Safety Procedures 
S.pneumoniae serotype 6B approved by public health England was used for inoculation. A laboratory 
manual was formulated with all the procedures in accordance with good clinical practice. This highlighted 
risks such as spill of bacteria, temperature regulation to store samples and bacterial stock along with a 
standard operating protocol to follow in an emergency. All laboratory staff were adequately trained in 
laboratory safety procedures. This reduced biological and chemical hazards within the laboratory. Health 
and safety regulations for research with human tissues / infectious agents were always followed.  
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 The Data Monitoring and Safety Committee (DMSC) 
A DMSC has monitored EHPC studies for 8 years and provided advice to the PI and asthma study team, ours 
consisted of two professors – one internal at LSTM and one external was available to provide advice and 
guidance to the principal investigator (PI) and the research team on any serious adverse events. An interim 
safety report was sent to the DMSC on completion of the first six step two participants, and a full the safety 
report containing information on all participants enrolled and inoculated was provided on completion of 
the study. An annual safety report and end of study report with number of participants recruited and 
inoculated was sent to the NHS ethics committee also.  
3.6.5.1 Adverse Events (SAEs) 
These were documented and reported to the sponsor and the DMSC as soon as possible and serious 
adverse events were reported within 24 hours. There were no serious adverse events during the study. 
3.6.5.2  Serious Adverse Events (SAEs) 
An SAE is an adverse event or reaction that: (a) results in death (b) is life-threatening (c) requires 
hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability or 
incapacity (e) consists of a congenital anomaly or birth defect. Serious adverse events (SAEs) were reported 
to the DMSC within 24 hours and adverse events within a week of occurring. All research staff were aware 
of the relevant paperwork to complete in any such event. Any SAE would have been reported to the 
research ethics committee (REC) and study stopped pending their review and guidance from the DMSC. 
 Data Management and Analysis Methods  
The data was collected using specifically designed case report forms. For analysis Statistical Package for 
Social Sciences (SPSS) version 22 and Graph Pad Prism version 5 were used. The statistical tests are 
described in each section in detail.  
 
Methods – Effect of Asthma on Immune Response to Pneumococcus Page 85 
 Comparative data from healthy controls  
The comparative data from healthy controls came from 4 different studies as described below. 
 Microbiology Comparisons – colonisation rates and density  
For comparison I used age-matched healthy controls from an influenza vaccine study (Sep 2015- Mar 2017), 
with identical methods and sampling, although participants received intramuscular tetravalent inactivated 
influenza vaccine either 3 days before or after inoculation with pneumococcus (209). This study was 
conducted simultaneously with the asthma study. Ideally I should have included an arm of healthy controls 
in parallel to the asthma study, as the flu vaccination may have affected the immune response to 
nasopharyngeal colonisation. However, due to time constraints and limited resources this was not possible.  
 Anti-capsular Polysaccharide IgG 
The data for healthy controls came from the control arm of an earlier EHPC study, with a similar protocol 
and identical general inclusion and exclusion criteria except for defining history of respiratory disease in 
asthma and its absence in healthy controls. This study looked at the effect of PCV 13 on nasopharyngeal 
colonisation in healthy volunteers. This was double blind randomised controlled trial and participants were 
either assigned to PCV 13 or hepatitis A vaccine group. They were subsequently inoculated with 
S.pneumoniae 6B and nasal wash samples collected at different time points to look for colonisation by 
classical microbiology culture techniques (152). The comparative data is from healthy controls who 
received hepatitis A vaccine and serum samples for IgG to 6B polysaccharide were processed using the 
same ELISA protocol in our lab as described in section 3.5.3. 
 Anti-pneumococcal protein IgG 
The comparative data is from a dose ranging study performed by our group designed to examine the 
immunising effect of a single colonisation episode in healthy volunteers (175). The study protocol and 
general inclusion and exclusion criteria were similar to our study; the only difference being the presence of 
asthma in our cohort and lack of any underlying medical condition for the healthy controls. Participants 
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were inoculated with an increasing dose of S.pneumoniae ranging from 10000 cfu to 160000 cfu. Nasal and 
serum samples were collected before and after inoculation. 
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4 Results – Experimental Colonisation rates, 
density and antibody levels in Asthma 
 Introduction  
In this chapter I discuss the results from the study. The research questions were:  
• do people with asthma have higher experimental colonisation rates compared to healthy controls? 
• is experimental colonisation affected by clinical characteristics of asthma?  
•  is the systemic immune response to experimental colonisation different in asthma compared to 
healthy controls?  
Clinical features may help identify asthma control and compliance with medication such as high FeNO 
suggests poor compliance or inadequate dose of ICS (222).  
Eosinophils and FeNO are important biomarkers of asthma diagnostic pathway (222), and if found to 
determine colonisation may help identify patients at risk of colonisation and subsequent disease. 
Forced expiratory volume in one second (FEV1) and PEFR variability are used to define asthma severity with 
low FEV1 indicating severe disease and PEFRs to monitor the condition and describe exacerbation severity 
(<33% predicted life threatening, 33-50% very severe, 50-75% moderate) as well as recovery from an 
exacerbation (223). Both these are clinically important indicators of disease prognosis and it is important to 
understand if they influence colonisation in asthma to guide vaccination and determine risk of 
pneumococcal disease.  
Pneumococcal colonisation in the nasopharynx generates an inflammatory response (177) and acquisition 
is increased in pre-existing inflammatory conditions such as co-existing viral infection (224). The anti-
inflammatory action of ICS is important as it may affect colonisation acquisition, density, duration and 
subsequently its immunogenic response. Increased risk of pneumonia is seen in COPD patients on ICS (25), 
with conflicting evidence in asthma (27, 28). 
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 Asthma and an exacerbation in previous 12 months are risk factors for nasopharyngeal colonisation (30, 
131). A high bacterial density in the nasopharynx is seen in inflammatory conditions such as viral co-
infection and is associated with pneumonia (225). Both these factors are important for people with asthma 
as they not only have an increased risk of being colonised, but the underlying airway inflammation may 
increase the bacterial density during colonisation. We have previously shown that pneumococcal 
colonisation is immunogenic (175), and duration of colonisation is important to study in asthma as if 
reduced, it may not be immunogenic with possible impaired protection against future colonisation. An 
inability to clear colonisation may suggest increased propensity to disease.  
 Antibodies (IgG) to capsular polysaccharide (CPS) capsule are serotype specific and play an important part 
in prevention of pneumococcal disease (5). They opsonise the polysaccharide capsule increasing 
susceptibility of the bacteria to be attacked by the host immune cells. They may have a role in agglutination 
of bacteria at the mucosal surface and lead to a reduction in nasopharyngeal colonisation (150). 
Polysaccharide vaccine (PPV 23) is widely used globally and provides serotype specific immunity by 
stimulating a subset of B cells to produce serotype specific antibodies. In contrast, conjugate vaccines (PCV) 
produce T cell dependent serotype specific immunity and stimulate memory B cells (226, 227). PCV reduces 
serotype specific nasopharyngeal colonisation and hospitalisations from pneumonia (228).  
Functional antibodies to 12 pneumococcal serotypes are routinely measured in clinical practice in patients 
with chronic respiratory diseases, prone to recurrent chest infections. Often the results show suboptimal 
levels (low baseline levels if >6 of the12 checked <0.35 mg/dl), and patients are offered a polysaccharide 
vaccine. The response is measured 8 weeks post vaccination which if low a referral to an immunologist for 
further assessment is considered.  
I studied the levels before and after inoculation in people with asthma and compared to healthy controls, 
to determine if people with asthma have increased antibody levels in response to experimental 
colonisation, if baseline levels affect colonisation outcome and whether this is different to that seen in 
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healthy controls. The data for healthy controls came from the control arm of an earlier EHPC study, with a 
similar protocol and identical general inclusion and exclusion criteria except for defining history of 
respiratory disease in asthma and its absence in healthy controls. This study looked at the effect of PCV 13 
on nasopharyngeal colonisation in healthy volunteers. This was double blind randomised controlled trial 
and participants were either assigned to PCV 13 or hepatitis A vaccine group. They were subsequently 
inoculated with S.pneumoniae 6B and nasal wash samples collected at different time points to look for 
colonisation by classical microbiology culture techniques (152). The comparative data is from healthy 
controls who received hepatitis A vaccine and serum samples for IgG to 6B polysaccharide were processed 
using the same ELISA protocol in our lab as described in Chapter 3. 
Anti-pneumococcal protein antibodies are serotype non-specific and an increase in titres is observed both 
post natural and experimental colonisation and infection (123, 175). 27 pneumococcal proteins are 
identified and their role in protection from colonisation and disease is under evaluation as potential targets 
for vaccine development, titres to several of these have been studied with varying results (229, 230).  
The serum samples were collected before and after inoculation same as for anti CPS IgG. The comparative 
data is from a dose ranging study performed by our group designed to examine the immunising effect of a 
single colonisation episode in healthy volunteers (175). The study protocol and general inclusion and 
exclusion criteria were similar to our study; the only difference being the presence of asthma in our cohort 
and lack of any underlying medical condition for the healthy controls. Participants were inoculated with an 
increasing dose of S.pneumoniae ranging from 10000 cfu to 160000 cfu. Nasal and serum samples were 
collected before and after inoculation.  
 Description of the study 
The study visits schedule and protocol are described in the methods chapter. Participants at BTS treatment 
steps 2 and 3 (described in Table 3) were all on preventive therapy with inhaled corticosteroids (ICS) at a 
minimum dose of 200 µg up to 800 µg beclomethasone equivalent (BDP). Steps 4 and 5 were not included 
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due to more severe disease, high dose ICS and/or frequent courses of oral corticosteroids in whom 
bacterial inoculation may have been associated with an increased risk of exacerbation. Study Overview is 
described in Figure 10. 
  
 






Timepoint Pre-screen -5 2 7 9 14 22* 29 
Baseline 
investigation 
✓        
Nasal wash  ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Nasal cells  ✓ ✓ ✓ ✓   ✓ 
FeNO ✓   ✓     
 
Figure 10: Study Overview: Study design showing timepoints for follow up visits.  
Participants were pre-screened up to 14 and at least 7 days before screening; at baseline full history, 
including relevant examination was done along with Spirometry, Peak Expiratory Flow Rate (PEFR), and 
baseline bloods All female participants had a pregnancy test before inoculation. Participants were asked to 
maintain a PEFR diary from then onwards throughout the study. After inoculation they were asked to send 
text messages with PEFR recordings and temperature (PEFR meter and thermometer were provided). *Only 
colonised participants. Fractional Exhaled Nitric Oxide (FeNO) 
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 Recruitment  
See methods chapter for details. I consented 95 participants of which 50 were inoculated (Figure 11 Panel 
A). The reasons for withdrawal are described in Figure 11 Panel B.  
Overall from June 2016 to April 2018, I recruited more than fifty percent participants from the university 
students, and in small numbers from other sources, such as information received from their GP, 
sensitisation at the LSTM’s open day, RLUH’s newsletter and word of mouth from volunteers participating 
in asthma and other research studies running simultaneously.  
 
After receiving completed questionnaires from primary care some participants were excluded due to other 
underlying conditions such as bronchiectasis, using CPAP therapy and recurrent exacerbations for asthma 
Figure 11. One participant was excluded for previous proven pneumococcal pneumonia.  
4.1.2.1 Recruitment Challenges and Reasons for Withdrawal:  
Our most successful recruitment was from the university, which had its own challenges; the students had 
changed their primary care provider in the previous 12 months, meaning the records were fragmented. Our 
commonest reason for exclusion from the study was lack of therapy with ICS (n=13) (Figure 11 Panel B).  
Participants on step 3 treatment and those with lack of reversibility on spirometry withdrew due to change 
in personal circumstance, whilst awaiting approval of study amendments and completion of six step 2 
participants to demonstrate safety.  
  
 

















Pre- screened n=66 
Screened n=54 
Inoculated n=50 








Figure 11: Study Recruitment: 
 Panel A) Flow chart showing recruitment and retention numbers; pre-screen visit – performed up to 14 days 
before inoculation for detailed history, examination, tests including FeNO, spirometry and full blood count 
(FBC); screen visit – up to 7 days before inoculation for baseline samples including nasal wash, nasal cells 
and bloods. Panel B) Graph with information on reasons for withdrawal and ineligibility – Underlying 
medical conditions include bronchiectasis, previous pneumococcal pneumonia, headaches, poorly controlled 
asthma; Unrelated to study – change in personal circumstance, moving out of the area, new job with time 
commitments; ICS dose above or below the inclusion criteria – commonest not prescribed any in the 
preceding 3 months or not using as prescribed. Withdrawn – no reason given  
  
0 2 4 6 8 10 12 14 16
Underlying Medical Conditions
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4.1.2.2 Study Completion  
 Only one participant did not complete the study. They required an increased dose of ICS due to low PEFRs 
(below 80% predicted), which was more than the protocol defined 800µg per day and was subsequently 
excluded from the study. Four participants withdrew after the screen visit, all due to a change in personal 
circumstances.  
I was unable to collect blood from one participant on the final visit. Nasal wash samples were available for 
all the time points for all the participants who completed the study.  
4.1.2.3 Statistical Analysis 
SPSS version 22 and GraphPad prism version 5 were used for analysis. Area under the bacterial density-time 
curve were calculated by trapezoid method of log10 (value+0.01). This addition was necessary as some 
values were 0 for density when participants were not colonised and these could not be log transformed.  
Colonisation rates were compared by chi square test. Continuous measures of colonisation by Mann 
Whitney U test and independent samples t test for non-normal and normal distributed data, respectively. 
All tests were two-tailed, with significance level of p<0.05. Spearman and Wilcoxon tests were used for 
correlation and paired-sample analysis respectively. Anti CPS and protein IgG values were log transformed 
before statistical comparison for normal distribution. 
  Clinical characteristics and demographics  
The demographics and baseline clinical characteristics of the 50 participants inoculated are described in 
Table 13 stratified by BTS Treatment category. The demographics were similar for participants on step 2 
and 3 treatment. Overall there were more female participants in our study making up 38 (76%) of the 
cohort. The percentage predicted of the Forced Expiratory Volume in 1 second (FEV1% predicted), blood 
eosinophil count and Fractional Exhaled Nitric Oxide (FeNO) were all similar with no statistically significant 
difference in step 2 and 3 participants. The baseline asthma control was good with median Asthma Control 
Test (ACT) score of 22 for both the groups. Participants on Step 3 treatment were on a higher dose of ICS 
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(Median [IQR] step 2 400 [400-400] vs step 3 450 [400-800] p=0.001). The importance of these clinical 
characteristics is described for asthma phenotyping in chapter 1.  
Table 13: Demographics and clinical characteristics for the asthma cohort according to BTS treatment step 




50 36 (72) 14 (28)  
Age (years) 
median (IQR)* 
22 (19.75-26.0)  21 (19.25-25.7) 22(19.75-27.0) 0.632 
Gender 
Female n (%) 
† 
38 (76) 28 (77.7) 10 (71.4) 0.637 
BMI (kg/m2) 




25.3 (23.1 - 27.6, 
6.7) 






0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.3 (0.1-0.4) 0.596 
FEV1% 
predicted 
Mean (95 CI, 
SD) ‡ 
95 (91-100, 13.28) 95 (91-100, 
13.48) 


















400 (400-400) 400 (400-400) 450 (400-800) 0.001 
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BTS Treatment Steps are part of the British Thoracic Society (BTS) guidelines on management of asthma, where treatment is increased in stepwise 
manner -starting from short acting beta agonist at step 1, to oral steroids at step 5. *Mann Whitney U Test, †Pearson chi square, ‡Independent 
Samples T test 
 Experimental Colonisation Rates in Asthma 
Our primary research question was to determine experimental colonisation rates in people with asthma. 
Overall 28 (56%) of the 50 inoculated participants were experimentally colonised (defined as positive 
bacterial culture from nasal wash at any time point). The demographics and clinical characteristics of the 
asthma cohort according to colonisation are described in Table 14. Only 2 participants of the 54 screened 




28 (56%) 19 (53%) 9 (64%) 0.462 
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Table 14 Demographics and clinical characteristics for the asthma cohort according to colonisation status 
     
 Whole Group Colonised Non-Colonised p value  
Number of Participants  50 28 (56) 22 (44) n/a 
Age (years) 
median (IQR)* 
22 (19.8-26.0)  22 (20-26) 21(19-24) 0.432 
Gender Female n (%) † 38 (76) 23(82) 15(68) 0.251  
BMI (kg/m2) 
Mean (95% CI, SD) ‡  





Blood eosinophils  
Median (IQR) * 
0.2 (0.1-0.4) 0.2 (0.1-
0.45) 
0.25 (0.1-0.4) 0.933 
§Blood Eosinophils >0.3 n (%) † n/a 16 (59%) 11 (41%) 0.615 
FEV1% predicted 
Mean (95 CI, SD) ‡  
95 (91-100, 13.28) 96 (91-101, 
12) 
93 (86-99, 14) 0.340 
^PEFR variability at baseline 
>12% † 
n (%) 
28 (66%) 15 (62.5%) 13 (72%) 0.508 
^PEFR variability post 
inoculation >12% † 
n (%) 
25 (62.5%) 17 (71%) 8 (50%) 0.182 
FeNO-ppb baseline 
Median (IQR) * 
25.5 (13.75-49.25) 20.5 (13.5-
37.5) 
29.5 (13.5-54.75) 0.287  
FeNO ppb 
Day 7 median (IQR) * 
25 (11-41.5) 25 (10-37) 26.5 (13.75-
54.75) 
0.526 
FeNO fold change (FC) Mean 
(SEM, SD) 





ll FeNO >40 ppb n** (%) † n/a 6 (37.5%) 10 (62.5%) 0.071 
ACT score baseline 
Mean (95 CI, SD) ‡  
22 (21-22, 2.0) 22 (21-22, 
2.1) 
22 (21-23, 1.9) 0.129 
ACT score Day 29 
Mean (95 CI, SD) ‡  
22 (22-23, 1.8) 23 (22-23, 
1.9) 
22 (22-23, 1.7) 0.816 
Inhaled Corticosteroid (µg) 
median (IQR) * 
400 (400-400) 400 (400-
500) 
400 (350-400) 0.208  
 
* Mann Whitney U Test, † Pearson chi square, ‡ Independent Samples T test, $ missing values **n = number of participants with a raised FeNO in each 
cohort.  ll Pearson’s chi square p=0.071 for a raised FeNO of >40 at baseline for colonisation and for change in FeNO from baseline * Pearson’s chi 
square p=0.367.  
§Pearson’s Chi square p=0.615 for a raised eosinophil count of >0.3 at baseline, Pearson’s chi square test p=0.274 for colonisation positive with 
steroid dose >400mcg, and for steroid dose >500mcg p=0.288, ^data available for 42 participants for PEFR variability at baseline, and 40 participants 




Results – Experimental Colonisation rates, density and antibody levels in Asthma  Page 99 
 Clinical Factors associated with experimental colonisation in 
Asthma  
The colonised and non-colonised groups were similar in demographics with the body mass index (BMI) higher 
in colonised participants (mean [95% confidence interval, 95 CI] positive 26.9 [24.7-29.1] vs negative 23.0 
[20.6-25.5] Independent samples t test p=0.019). There was no difference in any other clinical parameters 
measured.  
 Fractional Exhaled Nitric Oxide (FeNO) and Blood Eosinophils 
The FeNO levels >40 parts per billion (ppb) were used as a cut off for high levels as in clinical practice and 
blood eosinophil of >0.3 accepted as increased. The values were similar in the two groups as described in 
Table 15. 
Table 15 Colonisation status according to raised Fractional Exhaled Nitric Oxide at baseline, and increase 
from baseline and Blood Eosinophils 0f >0.3  
 Colonised (n=28)  Non-Colonised (n=22) 
+FeNO >40 ppb n (%) 6 (37.5%) 10 (62.5%) 
   
FeNO <40 ppb  22 (64.7%) 12 (35.3%) 
*Participants with an 
increase in FeNO from 
baseline  
12 (63.2%) 7 (36.8%) 
^Blood Eosinophils 
>0.3 n (%) 
16 (59.3%) 11 (40.7%) 
Blood Eosinophils 
<0.3 n (%) 
12 (52.2%) 11 (47.8%) 
n = number of participants with a raised FeNO in each cohort. The +Pearson’s chi square p value =0.071 for a raised FeNO of >40 at baseline for 
carriage and for change in FeNO from baseline * Pearson’s chi square p value=0.367. The ^Pearson’s Chi squares p value for a raised eosinophil count 
of >0.3 at baseline is 0.615 
 
I looked at participants with FeNO levels >40 and with eosinophils >0.3 to determine whether they 
influence experimental colonisation outcome. Out of our 50 participants 14 had a FeNO >40 ppb at 
baseline, of these 6 (37.5%) were colonised. This was not statistically different Pearson’s chi square p=0.07. 
I also looked at a change in FeNO level from baseline following inoculation, as this was measured at two 
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time points Table 15. Overall, 19 participants showed an increase in FeNO from baseline with 12 (63.2%) 
colonised, not statistically significant (Pearson’s chi square p=0.367). Fold change (FC) in FeNO values were 
calculated by dividing the value at day 7 by the baseline value was not statistically different in the colonised 
and non-colonised participants. 
In our cohort of participants 27 (54%) had a blood eosinophil count more than 0.3, of these 16 (59.3%) 
were colonised and 11 (40.7%) non-colonised (p=0.615). Within the entire asthma cohort, there was a 
positive correlation between FeNO levels and blood eosinophil levels (p<0.0001, r= 0.573). 
 Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow Rate 
Variability 
The median [IQR] FEV1% in our cohort was 95.5 (87.5-105), with no difference in colonised and (98.5 
[88.25-105]) and non-colonised (94.5 [84.5-103.5] p=0.340 independent samples t-test) Table 14. No 
significant reversibility (increase in FEV1% post salbutamol) was seen in colonised or non-colonised mean 
[SEM, SD] 6.15 [1.08, 5.55] vs 6.2 [1.51, 6.78] p=0.980, as described in Table 14.  
I asked participants to measure and record PEFRs for a period of six weeks. Two weeks prior to inoculation 
and for four weeks afterwards follow up. A PEFR variability calculator developed in house using excel 
(Appendix F) was used to calculate this. All the participants recorded 3 readings, morning and evening 
before taking their usual inhalers – the best reading was entered, and a value generated. Our cohort had a 
median of 14.6% PEFR variability [IQR] [9.6-21.1], and this was similar in BTS treatment Step 2 and 3 (14.3% 
[9.5-21.9] vs 14.8% [10.0-26.7] p=0.756 Mann Whitney U test) Table 13.  
I accepted a PEFR variability of 12% for the study, and this was not significant in colonised vs non-colonised 
participants median [IQR] 13.8 [9.5-22.6] vs 14.8 [10.4-21.1] p=0.684 Table 14. The number of participants 
with a PEFR variability of 12% colonised and non-colonised was similar (n, (%) 15 (62.5%) colonised vs 13 
(72%) p=0.508) non-colonised Table 16. 
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                                              †Pearson’s chi square, ‡ Independent Samples T test, * Mann Whitney U Test 
 
 Inhaled Corticosteroid Dose (ICS)  
The median dose of ICS in our cohort was 400 µg beclomethasone (BDP) equivalent IQR (400-400), with 
those on step 3 median (IQR) 450 µg (400-800) p=0.001 Mann Whitney U test. The dose of ICS was not 
associated with experimental colonisation outcome Table 17. I looked at participants on a dose of =<400 µg 














FEV1 >10% n 
(%) † 
4 (18%) 2(11%) 0.591 
Change in 
FEV1% Mean 
(SEM, SD) ‡ 
6.15 
(1.08,5.55)  
6.2 (1.51, 6.78) 0.980 
PEFR 
variability 
>12% n (%) † 







14.8 (10.4-21.1)  0.684 
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 † Pearson’s chi square p value for colonisation positive with steroid dose >400mcg = 0.274, and for steroid dose >500mcg =0.288 
 
 Body Mass Index (BMI) 
A high BMI was associated with the likelihood of colonisation in our study. The mean [95% confidence 
interval, 95 CI] for the whole cohort was 25.5 [23.5-26.9] with colonised participants having a higher BMI 






ICS >400 µg n (%) † 24(88.8%) 17(77.2%) 
ICS <400 µg n (%) † 3 (11.1%) 5 (22.7%) 
 ICS >500 µg n (%) † 7 (25.9%) 3 (13.6%) 
ICS <500 µg n (%) † 20 (74%) 19 (86.3%) 
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 Experimental Colonisation rates, duration and density in 
asthma compared to healthy volunteers  
In our study the rate of experimental colonisation and the density were not significantly different to age 
matched healthy control participants Table 18. For comparison I used age-matched healthy controls from 
an influenza vaccine study (Sep 2015- Mar 2017), with identical methods and sampling, although 
participants received intramuscular tetravalent inactivated influenza vaccine either 3 days before or after 
inoculation with pneumococcus (209).  
The median (IQR) dose of inoculum was 83417 (78333-85292) in asthma vs 78834 (76333-84167) p=<0.001 
in healthy controls. There were 82 (54.3%) females in the healthy controls, with a median age of 20 years; 
this was significantly different compared to participants with asthma Table 18. The number of colonised 
(nasal wash positive for bacterial culture at any time point) was 28 (56%) in asthma vs 68 (45%) in healthy 
controls. This was not statistically significant p=0.178 Pearson’s chi square. Colonisation at any time point 
was not significantly higher in asthma Table 18. 
The density as calculated using the area under time cure (AUC) was similar in asthma compared to healthy 
controls (median [IQR] asthma 63.49 [14.04-116.3] healthy controls 81.18 [48.15-104.5] p=0.060). The 
density was not significantly different at any time point Figure 12 A-C. The area under the density time 
curve was not affected when participants with negative time points were excluded Figure 12D, E. The 
duration of colonisation was significantly shorter in asthma compared to healthy controls (median [IQR] 14 
[7-29] vs 29[14-29]) p=0.034 Mann Whitney U test Figure 12F. The area under the time curve for density 




Results – Experimental Colonisation rates, density and antibody levels in Asthma  Page 104 
 
Table 18 Colonisation rates in Asthma compared to healthy Controls  





Demographics    
Median age (range) – year* 22 (20-26)  20 (19-22)         <.0005 
Female – no. (%) † 38 (76) 82 (54.3)          <0.007 






          <0.001 
Colonisation Status positive 
any timepoint– no (%) + 28 (56) 68 (45)            0.178 
Colonisation Status positive – 
day 2 (%) + 19 (38) 61 (40)            0.764 
Colonisation Status positive – 
day 7 (%) + 22 (44) 62(41)             0.715 
Colonisation Status positive – 
day 9 (%) + 17 (34) 60 (40)             0.470 
Colonisation Status positive – 
day 14 (%) + 19 (38) 50 (33)             0.528 
Colonisation Status positive – 
day 22 (%) + 
12 (24) 43 (28)            0.538 
Colonisation Status positive – 
day 29 (%) + 11 (22) 34 (23)              0.939 
Duration days median (range) 
* 
 14 (7-29)  29 (14-29)             0.034 
Colonisation Density log 
transformed AUC (cfu/ml) 
median (range) * 
 63.49 (14.04- 
116.3) 
 81.18 (48.15-       
104.5) 
             0.060 
 









Figure 12: Pneumococcal densities in participants with asthma and healthy controls  
A-C. Area under log-transformed bacterial colonisation density curve for participants colonised (positive 
bacterial culture from nasal wash) with pneumococcus at any time point who attended all visits up to A) day 
14 (n=asthma 27, healthy controls (HC) 67), B) up to day 22 (n= 27 asthma, 57 HC) and C) up to day 29 
(n=27 asthma, 59 HC). Individual volunteers are shown, and the lines represent median and inter-quartile 
range p values for Mann Whitney U Test are shown.  D-E: Bacterial colonisation density at each time point; 
D) all positive participants (positive bacterial culture from nasal wash at any time point) with negative time 
points included (participants attended for the visit and the nasal wash sample was negative for bacterial 
culture) (n=28 asthma, 68 HC), E) all positive participants at any timepoint with negative values removed 
(asthma n=19, 22, 17,19 ,12 ,11 at days 2, 7, 9, 14, 22,29 respectively, HC n=61, 62, 60, 50, 43, 35 at days 2, 
7, 9, 14, 22 and 29. Values are mean and 95% confidence interval for log transformed densities at each time 
point + 0.01 added to all values to allow log transformation). F) Cumulative clearance of colonisation (time 
point when nasal wash was negative for bacterial culture following a positive result at an earlier time point) 
in asthma vs HC at each time point. Clearance rates at each time point for asthma and HC; % clearance at 













































































































































Figure 13: Bacterial colonisation density for asthma  
A) dose of inhaled corticosteroid (ICS) >400µg n=7 or =<400µg n=21,all colonised (nasal wash positive for 
bacterial culture at any time point) participants with negative time points (nasal wash negative for bacterial 
culture) included B) ICS dose 400µg or <400µg all colonised participants with negative time points removed 
C) stratification by body mass index (BMI) >25 n=12, <25 n=16 all colonised participants with negative time 
points included D) BMI >25 or <25 all colonised participants with negative time points removed . Values are 
log transformed, bars represent mean and 95% confidence interval. 
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 Antibodies to S.pneumoniae 6B in response to experimental 
colonisation in asthma compared to healthy controls  
 Asthma Anti 6B CPS IgG  
The demographics of asthma participants are described in Table 19; data are available for 20 asthma 
participants (9 colonised and 11 non-colonised; the remaining 30 samples have not been processed using 
ELISA). These were performed in July 2016 on all the samples completed until then. Results for the 
remaining 30 participants who subsequently completed the study would be available following processing 
of these samples. Overall, there were more females in the asthma cohort 14 (70%) and the colonised and 
non-colonised asthma participants were similar in age (median [IQR] 22 (18 - 35) in positives vs 21 (19 - 22) 
in negatives p=0.539).  
Anti 6B CPS IgG was measured in asthma participants at baseline (screen visit at day -5, as explained in 
Methods section Subjects and timelines) at day 7 and at day 29. ELISA was performed as described in the 
Methods 3.5.3. Data are presented for samples collected at day-5 (baseline) and at day 29 after 
experimental challenge. The samples collected at day 7 were not included in the analysis as similar data for 
healthy controls was not available for comparison and antibody responses are usually reported after 4 
weeks post vaccination (123). The values were all log transformed before performing statistical analysis to 
normalise the data and allow parametric analysis. 
4.6.1.1 Asthma 
The baseline anti 6B IgG levels were similar in the colonised and non-colonised asthma participants; mean 
(standard deviation, SD) positive 6.65 ng/ml (0.83) vs negative 7.23 ng/ml (0.70) log transformed values, p= 
0.06 independent samples t test). A similar pattern was seen in the values post colonisation, mean (SD) 
positives 7.66 ng/ml (1.05) vs 7.08ng/ml (0.66), p=0.16, Figure 14A, C. The fold changes (calculated by 
dividing the post values by the baseline followed by log transformation) were statistically different in the 
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colonised and non-colonised participants. Mean (SD) colonised 1.03 ng/ml (0.69) vs non-colonised -
0.15ng/ml (0.25) p=0.0001 Figure 14D.  
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 Table 19: Asthma Anti 6B CPS IgG  
 Whole Group (N=20) Colonised (N=9) Non-Colonised 
(N=11) 
P value 
Demographics     
Age Median (IQR) – years* 21.5 (20 – 23.5) 22 (18 - 35) 21 (19 - 22) 0.539 
Female – no (%) † 14 (70) 7 (77.7) 7 (63.6) 0.786 
Inoculation dose CFU/nostril median 
(IQR) * 






Anti 6B anti CPS IgG (ng/ml) ^     
Baseline Mean (SD) ‡ 6.97 (0.79) 6.65 (0.83) 7.23 (0.70) 0.068 
  Post Inoculation (range) ‡ 7.33 (0.87) 7.66 (1.05) 7.08 (0.66) 0.164 
1Change from baseline in titre‡ 0.34 (0.76) 1.03 (0.69) -0.15 (0.25) 0.0001 
*Mann Whitney  U Test, †Pearson’s chi square, ‡Independent samples t test  
^Log transformed values – normally distributed, 1Calculated by diving the post value by baseline 
 





P value  
Demographics    
Median age (IQR) – years* 21.5 (20 – 23.5) 21 (19.0 – 22.75) 0.45 
Female – no. (%) † 14 (70) 31 (64.5) 0.67 
Median dose (range) – 
CFU/nostril ‡ 
81833 (78000 - 
85000) 
 81499(77833 – 
88500) 
0.59 
Colonisation Status positive – 
no (%) † 
9 (45) 24(50) 
 
0.71 
Sample availability – no. (%) *    
Baseline 20 (100) 48 (100)  
*MWT, †Pearson’s chi square, ‡Independent samples t test 
^Post inoculation sample availability 48 (100%) for healthy controls and 19 (95%) for asthma. 
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Figure 14: Log transformed Anti CPS IgG in people with asthma compared to healthy controls (HC): before 
and after experimental pneumococcal challenge  
 A) Asthma baseline and post levels in non- colonised (n=11) and colonised participants (n=9); p values for 
independent samples t test. B) HC baseline and post levels in non-colonised (n=24) and colonised 
participants (n=24); p values for independent samples t test C) Comparison of baseline and post levels in 
non-colonised and colonised asthma participants and HC D) Fold change from baseline (calculated by 
dividing the post value by baseline and log transformed after) in people with asthma and HC in non-
colonised and colonised participants; p value for independent samples t-test  
 
4.6.1.2 Anti CPS IgG in Asthma compared to Healthy Controls 
Anti 6B IgG CPS were measured in healthy control group in a similar manner at baseline (day -5) and after 
inoculation at day 21. The samples were stored and analysed according to the WHO standard ELISA 
protocol. The healthy controls were all inoculated with Streptococcus pneumoniae 6B, as part of a previous 
EHPC study as described earlier (152). The two groups were comparable in age and gender distribution and 
received a similar dose of inoculum, as described in Table 20. The number of experimentally colonised 
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There were no significant differences in antibody titres at baseline and post inoculation in colonised and 
non-colonised healthy control participants Table 21. A similar pattern was seen in asthma compared to 
healthy controls Table 19. The difference in fold change of antibody titres was statistically significant 
between the colonised and non-colonised healthy controls (Mean (SD) colonised 1.15 (0.86) vs non-
colonised 0.03 (0.21) Mann Whitney U test p=0.0001.  
A comparison of the two groups is shown in Table 21 and Figure 14C, D. The colonised and non-colonised 
participants in both cohorts show a similar pattern.  
 
Table 21: Baseline and post-challenge anti 6B capsular polysaccharide antibody concentrations in plasma: 
comparison of asthma and healthy control cohorts  
 
‡Independent samples t test, *Mann Whitney U test 
1Calculated by diving the post value by baseline  
  
 Colonised  Non – Colonised  
 Asthma Healthy Controls P value   Asthma Healthy Controls P value 
Demographics       
Median Age 
(range) – year* 
22 (18 - 35) 21 (19.0 – 26.5) 
 
21 (19 - 22) 20 (19 - 22) 
 




6.65 (0.83)  6.30 (0.63) 
 















baseline in titre 
Mean (SD) ng/ml 
1.038 (0.69) 1.15 (0.86) 
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 Anti-pneumococcal protein IgG 
This was a pilot study to determine if people with asthma show an increase in anti-pneumococcal protein 
antibody responses as these are of interest in vaccine development. Therefore, only a subset of samples 
were analysed. Data are available for 20 asthma participants (9 colonised and 11 non-colonised; processed 
using Meso Scale Discovery (MSD)). These were performed in July 2016 on all the samples completed until 
then. 
4.6.2.1 Demographics 
The demographics of asthma participants and healthy controls are described in Table 22. The comparative 
data for healthy controls came from a dose ranging study as described above. The healthy control 
participants were inoculated with increasing doses of 6B. The inoculation dose was statistically different 
between the colonised and non-colonised healthy control participants (median [IQR] 82000 cfu [51250-
128666] vs 21000 cfu [11166-29666] respectively p=<0.05). This was also seen on comparison of the 
asthma and healthy control groups (median dose [IQR] for asthma was 81833 cfu [78000 – 85000] vs 
healthy controls 49500 cfu [15916- 82000] p=0.001 Mann-Whitney U test.  
The two groups were similar in age and gender distribution, with no difference in the rates of colonisation. 
There were more females in the asthma cohort 14 (70%) and the colonised and non-colonised asthma 
participants were similar in age (median [IQR] 22 years (18 - 35); colonised vs 21 years (19 - 22) vs negatives 
p=0.539).  
4.6.2.1.1 Antibody responses to pneumococcal proteins in people with asthma responses 
Anti-pneumococcal protein IgG for 27 proteins were measured in the asthma cohort at baseline (screen 
visit at day -5, day 7 and day 29 as explained in Methods chapter. MSD was performed as described in the 
Methods section 3.5.4, in the WHO reference laboratory at the Institute of Child Health, University College 
London. Data are presented for baseline (collected at day-5) and post (collected at day 29). The samples 
collected at day 7 were not included in the analysis as similar data for healthy controls was not available for 
comparison and it was very early post inoculation to see an immune response. Antibody responses are 
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usually reported and measured at least 4 weeks post vaccination (123). The values were log transformed to 
normalise data before statistical analysis. 
4.6.2.1.1.1 Baseline  
Of the 27 proteins, the baseline anti-pneumococcal protein IgG titres were similar for 23 proteins in 
colonised and non-colonised asthma participants. Statistically significant difference was seen in the values 
of anti protein IgG against LytC, SP0609, Spr0057 and Spr1 p=<0.05 independent samples t-test in the 
colonised vs non-colonised asthma participants Figure 15A. 
4.6.2.1.1.2 Fold Change 
The fold change (FC) was calculated by dividing the value at day 29 by the baseline, and then log 
transformed to normalise. The change in titres of anti protein IgG from baseline was statistically significant 
for 13 out of the 27 measured proteins in colonised vs non-colonised asthma participants (PspC, NanA, 
PcpA, PcsB, PhtD, PhtDD, PhtE, PiaA, PiuA, PsaA, PspAUAB099, Rrg23F, RygA) p<0.05 Figure 16A.  
4.6.2.1.2 Healthy Controls 
The baseline titre for anti protein IgG was significantly different in healthy controls in colonised vs non-
colonised participants for two proteins: PcsB and Spr0057 p=0.02 Figure 15B. 
4.6.2.1.2.1 Fold Change  
The fold change (calculated by dividing the value at day 29 by the baseline, and log transformed for 
normalisation) was significant in colonised and non-colonised healthy controls for 3 anti protein IgG (PspA 
UAB055, PiuA, and SP2194 p<0.05 independent samples t test) Figure 16B.  
4.6.2.1.3 Healthy Control vs Asthma  
4.6.2.1.3.1 Baseline 
Of the 27 proteins, anti protein IgG titre for only one protein Spr0057 was significantly different in 
colonised vs non-colonised participants in both people with asthma and healthy controls. 
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4.6.2.1.3.2 Fold Change 
A similar pattern for fold change was seen for anti protein IgG against PiuA in both people with asthma and 
healthy controls. The change was significantly different in colonised vs non-colonised participants within 
each cohort.  
Comparing anti-pneumococcal protein IgG in fold change in between the asthma and healthy control 
cohorts in -  titres were significantly different for 14 proteins in non-colonised and for 8 proteins in the 
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Table 22 Demographics for Asthma and Healthy Control for anti-pneumococcal protein IgG 






Median age (range) – year* 21.5 (20 – 23.5) 22 (20-24) 0.361 
Female – no. (%) † 14 (70) 22 (53.6) 0.223 
Median dose (range) – 
CFU/nostril* 
81833 (78000 - 
85000) 
 49500 (15916- 
82000) 
 0.001 
Colonisation Status positive – 
no (%) † 
9 (45) 20 (48) 0.781 
Sample availability – no. (%)    
Baseline 20 (100) 41 (100)  
 
*Mann Whitney U test, †Pearson’s chi square 
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Figure 15: Serum IgG responses to 27 pneumococcal proteins at baseline measured using Meso Scale 
Discovery (MSD)  
 A) Asthma n=20 (11 non-colonised and 9 colonised) B) Healthy Controls n=41 (20 non-colonised and 21 
colonised). All values log transformed. Statistically significant difference in colonisation positive and 
negative log transformed values for IgG at baseline **p<0.05 – Independent samples t test. Bars represent 
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Figure 16: Serum IgG responses to 27 pneumococcal proteins measured with Meso Scale Discovery (MSD) – 
fold change (FC) values post inoculation divided by the baseline values and then log transformed.  
A) Asthma n=20 (11 non-colonised and 9 colonised) B) Healthy Controls n=41 (20 non-colonised and 21 
colonised). All values log transformed. Statistically significant difference in colonisation positive and 
negative log transformed values for IgG at baseline **p<0.05, borderline significant*<0.1 p >0.05 – 
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Figure 17: Serum IgG responses to 27 pneumococcal proteins measured with Meso Scale Discovery (MSD) – 
fold change (FC) values post inoculation divided by the baseline values and then log transformed; in non-
colonised and colonised participants. 
 A) Non-colonised participants with asthmatics n=11 vs Healthy Controls n=20 B) Colonised participants with 
asthma n=9 vs Healthy Controls n= 21). All values log transformed. Statistically significant difference in 
colonisation positive and negative log transformed values for IgG at baseline **p<0.05, borderline 
significant*<0.1 p >0.05 – Independent samples t test. Bars represent standard error of mean. P values were 
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 Discussion 
This is the first study to examine controlled challenge of an infectious bacterium in people with well 
controlled asthma, providing a unique opportunity to study experimental nasopharyngeal colonisation and 
its relation to clinical characteristics. The colonisation rates and density were not different in people with 
asthma compared to healthy controls. High BMI increased the likelihood of colonisation and it was 
unaffected by clinical characteristics such as FeNO and eosinophils.  
 Experimental Colonisation Rates, Density and Duration  
4.7.1.1 Asthma  
The experimental colonisation rates and density were not significantly different in asthma compared to 
healthy controls. This contrasts with cross-sectional observational studies which report high colonisation 
rates in asthma (132). However, these were conducted in general population with self-reported asthma and 
limited background information on medication, control, clinical characteristics and smoking history. These 
studies do not report objective measures such as FeNO and FEV1 which may indicate severity and control. 
The discordance with previous observations may be secondary to other factors such as a high dose of ICS 
therapy, poor control, more severe disease, or the limitations of data recorded from a single time-point. 
High colonisation rates amongst people with asthma with more severe disease could be seen secondary to 
higher doses of ICS, due to recurrent infections, or related more directly to asthma-related immune 
phenomena in the context of uncontrolled airway inflammation. 
Experimental Colonisation density was similar in asthma compared to healthy controls. High ICS dose 
(>400µg) and BMI (>25) were not associated with a difference in area under the density time cure. This was 
a small study of participants with moderate asthma on a maximum ICS dose of up to 800µg. A dose of more 
than 400µg did not increase or reduce the density of colonisation. Pre-existing inflammation is seen to 
increase the colonisation density, and this may be seen in participants with uncontrolled airway 
inflammation as a result of severe, refractory disease or poor compliance. Our participants on a moderate 
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dose of ICS, had well controlled asthma with good compliance, which may explain a lack of observed 
difference.  
BMI was associated with increased likelihood of colonisation. I looked at density in participants with a high 
BMI (defined as >25). There was no difference in the area under the density time curves for those with a 
BMI of more or less than 25. As obesity is associated with low level inflammation – a higher BMI may lead 
to increased colonisation density, however I have small numbers in my study with a median BMI in the 
normal range and this may explain a lack of difference. 
The duration of experimental colonisation is significantly reduced in asthma. This may be due to underlying 
airway inflammation, which could be increased further and helps clear the bacteria in a timely manner. A 
short duration of colonisation may lead to lower colonisation rates in asthma in observational studies – as 
an episode may be cleared before sampling. However, observational studies report an increased rate of 
colonisation which may be secondary to underlying disease related factors as described above, such as 
severe uncontrolled disease with increased airway inflammation – facilitating colonisation by providing for 
example increased bacterial attachment sites such as PAFRs. 
Nasopharyngeal colonisation is cleared by inflammatory cells recruited to the nasal mucosa (177). Faster 
clearance in a pre-existing inflammatory environment as in asthma may lead to a diminished mucosal and 
systemic immune response, as we have previously shown that colonisation is immunogenic (175).   
4.7.1.2 Asthma vs Healthy Controls 
A number of compositional differences in the asthma and control cohorts could have contributed to our 
results independent of airways disease. The number of female participants and the inoculation dose were 
significantly different in healthy controls compared to people with asthma. The median inoculation dose 
was lower in healthy controls and this may have reduced experimental colonisation (175). The difference in 
gender distribution and small numbers may impact on our result. Previously male gender has been 
associated with increased colonisation (131) and our cohorts had more females. An increased experimental 
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colonisation likelihood from a high BMI may also be independent of asthma as I do not have data in the 
healthy controls. In addition, the healthy control studies were carried out at different times of the year and 
seasonal variation in colonisation may affect the results. 
 Clinical Characteristics  
4.7.2.1 FeNO and blood eosinophils  
Levels of FeNO and blood eosinophils were not significantly raised in our cohort of colonised asthma 
participants, who all had well controlled asthma as recorded by objective (PEFR, spirometry) and subjective 
measures (ACT score). A blood eosinophil count of >0.3 or a FeNO of >40 did not affect colonisation 
outcome. A high FeNO and blood eosinophil count is seen in poorly controlled disease either refractory to 
therapy or inadequate compliance.  
FeNO is a marker of airway inflammation used for diagnosis and management of asthma in current 
guidelines (222). A raised FeNO and blood eosinophil level despite adequate therapy prompts a discussion 
for change in treatment such as increasing dose of inhaled corticosteroids or if requiring repeated courses 
of oral corticosteroids consideration for monoclonal antibodies. The colonisation rates may be higher in 
participants with severe asthma, with a reduced duration and an increased density. 
Blood and sputum eosinophil levels correlate and levels in blood are routinely used to guide therapy with 
steroids and specialised treatments such as monoclonal antibodies targeted against interleukin 5 (IL) (118, 
231). A blood eosinophil level of >0.3 is accepted as raised for biological treatment in asthma (118). A study 
of participants with severe asthma may address this but would be challenging to perform.  
4.7.2.2 Inhaled Corticosteroids 
Dose of ICS was not associated with an increase in colonisation rate and density in our cohort of 
participants with well controlled asthma. Therapy with ICS is aimed at reducing airway inflammation (93) 
and FeNO readings are used for monitoring in clinical practice, with high levels suggesting poor control, 
inadequate dose or lack of compliance of ICS  (50, 232, 233). Adequate dose of ICS with good control may 
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explain low levels of FeNO and blood eosinophils in our study. Poor asthma control secondary to 
uncontrolled airway inflammation may increase colonisation in severe asthma. 
4.7.2.3 Asthma Severity and control  
All our participants had well controlled asthma with a normal FEV1 and no significant reversibility and good 
peak flow rates >80% predicted at baseline. These did not alter during study follow up, and one participant 
who had reduced PEFR was excluded due to an increase in the dose of ICS. PEFR variability of >12% did not 
influence colonisation outcome. The subjective control as measured by the ACT score was good.  
Spirometry measurements and peak expiratory flow rate variability are used to diagnose and monitor 
asthma in clinical practice (223). They are both easy to record and interpret.  
Asthma treatment is targeted to achieve adequate control defined as normal spirometry, symptom free 
and PEFR >80% predicted (223). To ensure safety, I included only these participants. The PEFRs did not alter 
after inoculation – which may have induced inflammation as a result of colonisation, thereby leading to 
increased symptoms.  
Experimental colonisation may be altered in participants with low FEV1 and low PEFRs. They may have a 
high rate of colonisation with increased density and reduced duration.  
The guidelines recommend increasing or reducing ICS dose according to symptoms and disease severity, 
with the aim to achieve a dose with no symptoms and minimal side effects (31, 223). Our participants were 
on moderate and adequate dose of ICS and had well controlled asthma.  
4.7.2.4 BMI 
Our findings show that a high BMI is associated with colonisation, however our participants were not obese 
– defined as a BMI > 30. Asthma phenotyping has led to an appreciation of obesity asthma, often severe 
and therapy resistant and these patients require a larger proportion of resources (37, 234). In such cases 
obesity might be an iatrogenic component, perhaps secondary to repeated courses or maintenance use of 
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oral steroids, or may be an independent driver of disease (55). There is evidence to suggest obesity alters 
eosinophil recruitment, with an increase in sputum IL5 and submucosal eosinophils, but does not affect 
sputum eosinophils (62, 235). These findings may be independent of asthma, as I do not have similar data 
in healthy controls for comparison and there are no data to link obesity to nasopharyngeal colonisation in 
epidemiological studies.  
4.7.2.5 Anti 6B CPS IgG  
Amongst those with asthma, colonisation was associated with larger fold-increases in anti-CPS antibody 
titre than when individuals were not colonised. The levels at baseline were not significantly different in 
colonised and non-colonised participants.  
These results are similar to healthy controls as previously published (175) and no significant differences are 
seen between the two groups, despite a shorter duration of colonisation in asthma. The values in healthy 
controls were from samples taken at day 21 and those from asthma participants at day 29. Given the 
patterns of IgG production after inoculation, it would be expected to continue to rise until at least 28 days, 
and a difference may be seen between the two groups if samples were collected at day 29 in healthy 
controls. The healthy controls all received hepatitis A vaccine which may have affected the  antibody 
response in this cohort. However, this did not reduce experimental pneumococcal colonisation compared 
to the PCV arm in the study. This is a weakness of our comparative data and I speculate that as it did not 
affect the primary outcome of pneumococcal colonisation, it is unlikely to have lead to an increase in 
pneumocccal polysaccharide antibody levels.     
In future, I intend to assess the anti-CPS function in asthma and control populations in order to 
complement the absolute concentration data. This will use opsonophagocytic assays to test the 
independent effect of the antibody while controlling for other factors, but results are not available yet. Our 
future re-challenge study arm will address this; colonised participants will be re-challenged with the same 
strain and with anti CPS IgG measurements taken at baseline and post inoculation. In our previous work we 
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have shown that anti CPS antibody levels protect against future carriage acquisition in healthy controls 
(175). These results may also be affected by disease severity specially in those participants who require 
multiple courses of oral corticosteroids for recurrent exacerbations. 
 
4.7.2.6 Anti-pneumococcal protein IgG 
An overall trend of increase in fold change was seen in antibody titres against pneumococcal proteins in 
colonised asthma participants. This was a pilot study and only a subset of randomly sampled participants 
were included in the MSD analysis. The pattern is similar as seen in healthy controls. 
The titres for anti protein Ig antibodies fall in non-colonised participants in asthma and in some healthy 
controls. The reason for this is not clear and could be due depletion of antibodies from clearance of 
colonisation or an error in sample processing. This requires a larger cohort to study the trend and perhaps 
determine opsonophagocytic assays in non colonised and colonised participants to understand the 
functional ability of these antibodies. 
However, the comparative data for healthy controls is from a dose ranging study, with a lower dose of 
inoculum and the samples were collected 2 weeks after the challenge. This may have affected the results. 
The asthma study participants were incoulated with a dose seen to achieve experimental colonisation rates 
of 50% in healthy controls based on earlier EHPC studies. The lower dose particpants in the healthy control 
study did not experimentally colonise and these results may have been different if all the healthy control 
participants received a similar inoculum dose. These data need to be interpreted with caution considering 
the inoculation dose was different in the healthy control arm, and samples were collected at differing time 
points. 
There is variation in the number and type of proteins between the two groups. This may be due to small 
numbers in the both cohorts, specially asthma, and therefore results need to be interpreted with caution. 
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Overall titres for 13 pneumococcal protein IgG increased in asthma cohort compared to only 3 healthy 
controls. This analysis has been performed with a view to generating hypotheses for future research. I have 
therefore, not taken into account multiple testing, which may lead to these results by chance. Correction 
for multiple testing, on the other hand, is associated with type 2 statistical error which may not be 
appropriate in exploratory analysis (236). 
A general trend of increase in titres from baseline in colonised asthma participants supports the use of 
these proteins as targets for novel vaccines (124). Pneumococcal choline-binding protein A (PcpA), 
genetically detoxified pneumolysin (PlyD1, PdA, PdB), chemically detoxified pneumolysin (dPly), and 
Pneumococcal histidine triad D (PhtD) and E (PhtE) (229, 237-239) are already widely studied antigens. 
PcpA is an important protein seen in clinically identified strains of S.pneumoniae (124). Further 
investigation in a larger asthma cohort across the disease spectrum is required to address the question 
whether a protein antigen-based vaccine would be protective in people with asthma. 
 Summary 
To summarise, I have demonstrated that experimental colonisation rates and density are similar in people 
with well controlled asthma compared to healthy controls. The duration of colonisation is significantly 
reduced in participants with asthma and the systemic immune response to pneumococcal polysaccharide 
(anti CPS IgG) and protein antigens (anti-pneumococcal protein IgG) is not significantly different in 
comparison to healthy control participants. 
Overall, the data suggest some differences which may be related to treatment or the underlying disease. 
However, no profound difference in immune responses was found, suggesting that a vaccine in asthma 
should not perform significantly differently than healthy population. It is as yet undetermined if people 
with asthma have a substantially increased specific risk of disease which would support targeted 
vaccination outside of usual prevention programmes. 
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5 Single-use and Conventional Bronchoscopes 
for Broncho alveolar Lavage in Research: A 
comparative study (NCT 02515591)  
This is a published manuscript from BioMed Central (BMC) Pulmonary Medicine from May 2017 
(https://www.ncbi.nlm.nih.gov/pubmed/28476111)(240). 
 Background 
Bronchoalveolar lavage (BAL) samples can provide valuable information for diagnosis and ongoing 
management of asthma. Studying lower airway immune cells and microbiome in asthma may inform 
future therapies and allow development of new diagnostic tests. Research is ongoing to find new 
modalities for improving diagnostic methods, as currently available tests have sensitivity in adults in 
the region of 50%, with false positives and negatives well recognised. There is interest in studying 
volatile organic compounds and particles in exhaled air, multiple breath washout (used to study 
ventilatory heterogeneity) and impulse oscillometry (to study peripheral airway resistance) to 
predict a diagnosis of asthma (241-243). BAL can aid in investigating and validating findings to 
develop these non-invasive methods further by providing information on inflammatory and immune 
processes within the lungs. All the information together from blood, breath, sputum and BAL can 
guide phenotyping and targeted therapy development.  
For the established therapies such as monoclonal antibodies, BAL can be useful to help understand 
the changes in for example airway remodelling in patients established on such treatment and 
provide a comparison of before and after (244, 245).  
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Many asthma research studies now include BAL samples as standard in a subset of patients and 
developing a safe and efficient technique is very relevant. I have demonstrated in this study that 
single use bronchoscopes can be used safely to obtain an adequate BAL sample and would extend 
this to future asthma studies involving EHPC.  
Flexible bronchoscopy is widely performed in adults and children for investigation of pulmonary 
pathology (246, 247). Broncho alveolar lavage (BAL) sampling is used to study innate, cellular and 
humoral immune responses, determining the cell population profiles that can facilitate the diagnosis 
of various diffuse lung diseases (180, 197-200). It is used in early phase drug development studies and 
has a well-proven safety record in both research and in clinical applications. BAL is easily performed 
and well-tolerated with rare complications(248-250). 
Typically, conventional flexible bronchoscopes are used but they are associated with significant costs 
related to initial purchase, ongoing maintenance, and sterilisation (251, 252). Single use 
bronchoscopes offer an alternative (251) and are currently used in many UK NHS trusts for both 
emergency and elective airway intubations (253). Single use scopes are more portable, and might also 
improve working efficiency (252). Their efficacy for research studies has not yet been demonstrated, 
notably in research BAL the cell number and viability, and the returned volume of epithelial lining fluid 
is critical. Maximising the volume of BAL fluid returned has potential advantages to both researchers 
and participants: procedures that return less than 100 mL are more frequently associated with side 
effects such as cough, pleuritic chest pain and fever. Larger total instilled volumes of a minimum of 
100 mL and a recommended standard 240 mL using standard 4 x 60 mL aliquots have therefore been 
recommended by the European Respiratory Society (ERS) to improve standardization when more 
efficient alveolar sampling and accurate quantitative measurements are required (254). For cellular 
studies, function and viability are important, and may be maximised by the use of manual suction 
which minimises cellular shear forces (248). Rapid processing by designated laboratory staff highly 
trained in handling of BALF (BAL fluid) samples is ideal. However, it should be noted that there is no 
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strong relationship between the volumes returned and cell numbers obtained (unpublished data from 
our group).  
This study presents a comparison of single use disposable bronchoscopes and conventional 
bronchoscopes with regards to BAL volumes, cell yields and viability using each method in healthy 
controls, to establish a safe and effective sampling method which can be used in people with asthma. 
 Methods 
The aim of the study was to compare the BAL volume yield, total cell yield and viability between 
samples obtained using single use and conventional bronchoscopes and develop a safe sampling 
method using single use bronchoscopes to be extended to people with asthma post experimental 
pneumococcal challenge in future. The single use, flexible bronchoscopes were provided free of 
charge for use by Ambu®, with no input in the study design, analysis or manuscript drafting. 
Table 23 compares different features of the single use and flexible bronchoscopes. 
 Recruitment 
We enrolled healthy volunteers aged 18 - 55 years old, to undergo bronchoscopy using the Ambu® 
ScopeTM Regular 5.0/2.2 single-use flexible intubation bronchoscope. The study was carried out in the 
Clinical Research Unit (CRU) at the Royal Liverpool University Hospital (RLUH). The primary aim was to 
compare the BAL volume yield (mL), cell yield (total cell number) and proportion of viable cells 
(alveolar macrophages [AM] and lymphocytes), with recent data from procedures using conventional 
bronchoscopes. Conventional procedures were performed on 50 healthy volunteers recruited at the 
same site with identical inclusion and exclusion criteria. The demographics are described in Table 24.  
A physical examination including vital signs was performed. A detailed history of complications 
associated with other procedures or trauma was obtained, and risks for bleeding sought according to 
guidelines (200), specifically medications (e.g. clopidogrel, aspirin, Coumadin, heparin), and relevant 
medical conditions (e.g. uraemia). Exclusion criteria were: a history of allergic reaction to 
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benzodiazepines, or any anaesthetic agent; smoking history of >10 pack years; any tobacco smoking 
in the preceding 3 months; pregnancy; abnormalities of screening blood tests (haemoglobin, white 
cell count, platelets, liver transaminases, bilirubin, renal and clotting profile).  
 Bronchoscopy and Broncho alveolar lavage 
Bronchoscopy was carried out as a day case according to previously published protocol by our group 
(248). Briefly, local anaesthesia was attained using topical lidocaine gel and spray, with further 4% 
lidocaine administered to the larynx and 2% lidocaine to the bronchial tree via the scope. Warmed 
0.9% saline was instilled to the right middle lobe in sequential aliquots (60 mL, 50 mL, 50 mL and 40 
mL), with aspiration into a sterile syringe using gentle manual suction, as in our previous BAL studies. 
BAL yields were recorded, and fluid transported immediately to the laboratory on melting ice (248). 
We used continuous monitoring of heart rate, blood pressure and oxygen saturations during the 
procedure, with supplemental oxygen given by nasal cannula. 
All procedures were carried out by one of two senior bronchoscopists, experienced in obtaining BAL 
for research purposes. Hospital procedures required that conventional bronchoscopy was performed 
in the surgical theatres, whereas flexible bronchoscopy was performed in the research ward: this was 
the only difference between the groups.  
 Sample processing 
BAL fluid (BALF) was filtered through double layered gauze to remove mucus plugs. Cells were pelleted 
by centrifugation (1500rpm for 10min at 4oC) and washed with 50 mL cold RPMI medium (Gibco™ 
RPMI 1640 Medium) containing antibiotics (Penicillin, Neomycin and Streptomycin, Sigma-Aldrich, 
Sigma Chemical Co. St. Louis, MO, USA). The centrifugation step was repeated once, and the cell pellet 
was re-suspended in culture medium, with the addition of 10% FBS Gibco-Invitrogen (Life 
Technologies GmbH, Eggenstein, Germany). Cell suspensions were examined as 5 times diluted 
in trypan blue for counting and viability assessment using a haemocytometer.  
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 Statistical analysis  
Primary outcome measures were compared with values from the preceding 50 conventional 
procedures using the Mann Whitney U Test. Statistical analyses were performed with Graph Pad 
Prism version 5.0, Graph Pad Software, La Jolla, CA, USA). It was estimated that 8 volunteers in each 
group (16 total) will provide a 90% power to detect non-inferiority 1.5 times the standard deviation 
of the expected return BAL volume. 
 
 Results 
Ten participants (6 male), mean age of 23.4 years (range 20-26 years) were enrolled. All participants 
were intubated nasally, and only one requested sedation (midazolam 3mg used). The median BAL 
volume yield from the single-use bronchoscopes was 152 mL (IQR 141-166 mL) as compared to 
conventional 124 mL (110-135 mL), p<0.01 Figure 18. The median total cell yield from single-use 
bronchoscopes was 7.33 x 106 (5.13x106 – 9.80x106) compared with 7.0x 106 (4.53 x 106 – 1.64x107) for 
conventional procedures, p=0.61 Figure 19. The median cell viability for samples from single use 
bronchoscopes was 98.5% (93.8-100) compared to 98.2% (93.7-100%), p=0.75 Figure 20. The 
comparison for the demographics is described in Table 24.  
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Table 24: Demographics of participants for Single use and Conventional Bronchoscopes 
 Single-use (n=10) Conventional (n=50) 




Males (%) 6 (60%) 19 (37.2%) 
#Un-paired T-test, SD standard deviation 
 
 
Figure 18: BAL Fluid Volume Yield (mL) from Conventional vs Single-use Bronchoscopes 
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Figure 19: Total cell yield (no.) from Conventional vs Single-use Bronchoscopes 
 
 




Broncho alveolar lavage with single-use flexible bronchoscope achieved greater BAL volume yields 
than with conventional bronchoscopes. There was no significant difference between the cell yield and 
viability between the methods. 
Single-use bronchoscopes have been evaluated in the critical care setting with favourable evaluation 
for bronchoscopy, tracheostomy, intubation and suction (251). Our group has experience of over 1500 
research BALs, and the procedures in this study were performed by senior bronchoscopists with 
extensive experience of BAL for research purposes; allowing good comparison with the use of 
conventional bronchoscopes. BAL volume yields were similar in male and female participants in our 
study, as seen in other studies(255). 
BAL sampling has been used for investigating, diagnosing and profiling pulmonary conditions such as 
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information on alveolar cell profiles and immune responses to guide therapy. BAL samples from 
participants colonised with pneumococcus and with pneumococcal pneumonia have been used to 
study mucosal immune responses (201, 202).  
The greater BAL volume return achieved with single-use bronchoscopes could lead to reduced risk of 
post-procedural side effects such as cough, pleuritic chest pain and fever, which may improve 
tolerability and participant comfort. However, I have not systematically collected these data.  
Single use flexible bronchoscopes have the potential for use in pharmaceutical preclinical and clinical 
studies for medicine development.  
 Bronchoscopy in Asthma 
Samples from BAL are helpful in defining asthma phenotypes and targeting therapy. This has been 
used in asthma for some time mostly using conventional bronchoscopes. This technique using single 
use flexible bronchoscopes can be used in asthma. We have previously shown increased activity of 
alveolar macrophages in experimentally colonised healthy controls, and it would provide a helpful 
insight into the lung immune responses in both colonised and non-colonised asthma participants. 
This would help research into new medications to treat asthma according to phenotype and guide 
vaccine development. This can also be used to study the effect of new therapies on airway 
remodelling. Using EHPC we can conduct early phase studies with a small cohort of participants. This 
sampling method is safe in healthy controls and may be extended to include people with asthma 
post challenge in future. 
 Conclusion 
Single-use flexible bronchoscopes can be used to obtain BAL for research purposes to study immune 
responses and in early phase drug development studies in healthy controls and can be implemented 
in asthma to obtain adequate BAL samples.  
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6 Discussion  
In this thesis, I have described the first study investigating human pneumococcal challenge in people 
with asthma. Our literature review highlights an interesting overlap between the pathophysiology of 
asthma and pneumococcal colonisation, with airway inflammation being common to both.  
Preventing nasopharyngeal colonisation is an important step in controlling invasive disease from the 
bacterium. Mucosal innate and adaptive immune responses form part of the frontline defence in 
preventing colonisation. This is complemented by systemic responses through secretion of cytokines 
by T cells such as interleukin (IL) 17 by Th17 cells. IL17 enhances inflammatory response by 
recruitment of neutrophils and macrophages to help with timely clearance of the bacterium from 
the nasopharynx and in asthma promotes fibroblast proliferation leading to airway remodelling. The 
balance of this inflammatory mechanism may play an important part in pneumococcal disease in 
asthma – increased exposure may lead to reduced antigen exposure and subsequent poor future 
protection whereas reduced secretion may result in delayed clearance and perhaps an increase in 
disease.    
Nasopharyngeal pneumococcal colonisation in early life is associated with increased risk of 
developing asthma later (35). Asthma and an exacerbation in the preceding 12 months can affect the 
likelihood of becoming colonised by S.pneumoniae (131).  
Invasive pneumococcal disease and pneumonia are increased in asthma, and the response to 
vaccination is unclear along with limited information on baseline immune responses. This may be 
due to the underlying disease mechanisms or related to treatment. These factors require 
investigation, to reduce burden of pneumococcal disease affecting people with asthma and to 
achieve better symptom control as bacterial infections may cause exacerbations leading to a 
deterioration of symptoms. 
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 Using experimental pneumococcal challenge in a well characterised cohort of people with moderate 
asthma on ICS therapy, I have shown:  
• The rate and density of experimental nasopharyngeal colonisation are similar compared to 
healthy controls 
• The duration of colonisation is significantly shorter compared to healthy controls  
• Clinical characteristics such as FeNO, blood eosinophils, spirometry and PEFR do not affect 
experimental colonisation 
• A trend towrds an increased likelihood of experimental colonisation with increasing BMI 
• The systemic immune response (anti CPS IgG and anti-pneumococcal protein IgG) is similar 
to healthy controls 
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 Colonisation Rates, Density and Duration  
The colonisation rates and density were not significantly different in our cohort of well characterised 
asthma participants compared to healthy controls, suggesting that people with well controlled 
asthma are not at increased risk of pneumococcal colonisation.  
Our findings are in contrast to those from observational studies, which report high colonisation rates 
in asthma. These were conducted in general population with self-reported diagnosis of asthma and 
lack of information on objective and subjective measures of disease, treatment and compliance. The 
participants in these studies may have had sub optimally controlled, severe disease with poor 
compliance.  
All our participants were symptom free at the time of inoculation with markers of disease severity 
within normal range. This was due to careful participant selection and inclusion criteria which led to 
recruitment of asymptomatic volunteers on optimal treatment.   
 The colonisation rates and density were not associated to the dose of ICS in our study. All our 
participants were on moderate dose and a high dose of ICS may influence colonisation outcome – 
for example the anti-inflammatory effect may reduce mucosal immune response and lead to 
increased colonisation rates. Similarly, symptomatic asthma participants with uncontrolled airway 
inflammation despite therapy with high dose ICS may also have high bacterial colonisation rates and 
density secondary to for example increased bacterial attachment sites. Platelet activating factor 
receptor (PAFR) provides attachment sites for S.pneumoniae on the mucosal surface and in asthma 
leads to airway inflammation by activation immune cells, increased recruitment of inflammatory 
cells, vascular permeability and mucus production by goblet cells.  
 
I hypothesise that asthma participants with uncontrolled airway inflammation would have increased 
nasopharyngeal colonisation rates and density secondary to increased bacterial attachment sites for 
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instance. Although, excessive airway inflammation may contribute to a brisk mucosal immune 
response leading to early clearance of the bacteria and therefore they may have a shorter 
colonisation period. 
The duration of colonisation was significantly shorter in people with well controlled asthma 
compared to healthy controls. The shorter duration may be due to underlying airway inflammation 
in asthma, or an effect of immune profiles such as IL17 which facilitates clearance of colonisation. A 
shorter duration may be associated with a reduced systemic immune response. If colonising bacteria 
are killed, and antigen presentation takes place over a reduced time frame, I hypothesise that the 
absolute humoral responses would be lessened. The effect on T cell responses of a shortened 
window of antigen availability might also be important as both humoral and cell mediated immunity 
is required for protection from pneumonia and invasive disease (256). The concurrent use of steroids 
may alter the development of cell-based immunity by reducing the numbers of immune cells 
including macrophages and antigen presenting cells within the mucosa. These cells engulf the 
bacteria and present derived antigen via the major histocompatibility cell complex to T cells in the 
local lymphoid tissue. This subsequently leads to activation and differentiation of T cells and they 
stimulate B cells for antibody production and migrate from the lymphatic tissue to the infection site 
releasing cytokines to help clear the bacteria (257). There is interest in understanding the role of ICS 
in this mucosal immune pathway with BAL studies being undertaken in healthy volunteers on ICS 
(NCT02476825). There are no data available on duration of nasopharyngeal colonisation in asthma. 
I have explained this further in a diagram below. Uncontrolled asthma leads to increased airway 
inflammation which may be due to lack of compliance or despite high dose ICS with compliance as 
seen in patients requiring further treated with monoclonal antibodies. In those with poor 
compliance I speculate higher colonisation rates and rapid clearance due to inflammation, and in 
those with good compliance on high dose ICS I hypothesise increased colonisation rates with altered 
clearance – could be enhanced or slow secondary to the effect of ICS.  
 






My findings generate the following main questions:  
1. Are colonisation rates and density higher in uncontrolled asthma with a shorter duration? 
2. How does therapy with ICS affect colonisation outcome – rate, density and duration? 
I can address the first question by a pilot epidemiological study of asthma participants on high dose 
ICS. This would include two cohorts - symptomatic participants despite therapy and well controlled 
on high dose ICS. The selected participants with appropriate disease markers – for example – poorly 
Uncontrolled Asthma = Increased 
Airway inflammtion
Lack of Compliance 
Increased:  Colonisation and 
clearance 
Reduced duration 
With good compliance despite high 
dose ICS 
Increased colonisation 
Altered clearnce due to the effect of 
ICS 
Possible low Th2 and high IL17 profile 
Duration - altered, may increase or 
decrease
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controlled with more than 2 or 3 exacerbations in one year, ACT score less than 18; well controlled 
with none or 1 exacerbation per year and ACT score more than 20; would have nasopharyngeal 
samples collected at different time points over a 6 week period, to determine colonisation rates, 
density and duration. Participants for this may be recruited from a pre-existing research database or 
a national registry with predefined criteria. 
The second question may be addressed by studying healthy control participants treated with ICS for 
a period of 8 weeks – 4 weeks before bacterial challenge and followed for 4 weeks after in a similar 
manner using EHPC. This will require ethical approval and the exposure to ICS justified. This would 
have three cohorts of healthy control participants – not on any ICS, on moderate dose and high dose 
ICS. The results can be compared to historic healthy control EHPC studies and my asthma cohort.  
The results showing a shorter duration of colonisation with rates and density comparable to healthy 
controls in the context of observational studies showing increased risk of invasive pneumococcal 
disease in asthma require further investigation. Studies described above may address these with 
factors such as ucontrolled airway inflammation and therapeutic effect of ICS contributing to the 
increased disease burden in this patient population. Contribution of phenotype Th2 and Th17 may 
play a part in this as well. All these factors may contribute to an increased risk of pneumococcal 
disease seen in patients with asthma.  
 Clinical Characteristics 
Clinical characteristics defining the condition and phenotypes of asthma do not influence 
experimental colonisation outcome in this study. All my participants had normal lung function with 
absence of reversibility. FeNO and blood eosinophils were raised (defined as FeNO>40 and blood 
eosinophils >0.3) in a small number of participants but did not affect colonisation outcome.  
Factors such as blood eosinophils and fractional exhaled nitric oxide (FeNO) are simple measures of 
inflammation but are only raised in patients with poorly controlled disease. A small sample size of 
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well controlled participants may explain lack of these factors influencing colonisation. I do not have 
data on the effect of these factors from epidemiological studies.   
I speculate that asthma at the severe spectrum of disease may increase the likelihood of 
pneumococcal colonisation. Severe disease is defined by low FEV1, uncontrolled airway inflammation, 
recurrent exacerbations and increased use of healthcare resources. Suboptimal control may be 
secondary to inadequate therapy or compliance with ICS or sometimes despite maximal dose of ICS 
with good compliance. These patients then require treatment with new therapies such as 
monoclonal antibodies against IL5. The persistent eosinophilia seen in these patients leads to airway 
remodelling which may also affect immune responses and propensity to infection. Participants with 
severe and uncontrolled disease were excluded due to safety concerns.  
The questions from this observation for further study are: 
1. Is reduced lung function associated with nasopharyngeal colonisation outcome for example 
secondary to recurrent infections, persistent inflammation and airway remodelling?  
2. Are high FeNO and blood eosinophil levels associated with nasopharyngeal colonisation 
rates, density and duration?  
Both these questions could be answered by the epidemiological study described above of asthma 
participants on high dose ICS. In addition, to the inclusion criteria described, I would define 
parameters for FEV1, FeNO and blood eosinophils along with the dose of ICS in each cohort. The 
values would be in the normal range for the well-controlled arm and deranged (high FeNO) for the 
poorly controlled arm. FeNO and blood eosinophil levels would be measured at baseline and at 
follow up visits along with ACT scores. These measurements are useful to include as they are easy 
and non-invasive to perform and simple to interpret and monitor over time, although measuring 
lung function may be more useful.   
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 BMI 
A trend of increased likelihood of experimental colonisation is seen with a higher BMI being in 
people with well controlled asthma. The asthma cohort had a median BMI within the normal range. 
BMI has not been studied in the context of nasopharyngeal colonisation in asthma or healthy 
controls. Obesity related asthma is a recognised phenotype, which can be secondary to a high body 
mass index (BMI) or a consequence of the condition and treatment (55). Several factors may 
contribute to asthma due to obesity such as structural changes due to reduced lung volumes, airway 
compliance, altered airway mucosa and ageing processes. It is often late onset, affects women 
commonly and may be associated with oxidative stress. This may also be iatrogenic from 
transformation of early onset, uncontrolled allergic asthma treated with multiple courses of OCS 
(258).  
It is plausible that obesity affects nasopharyngeal colonisation independent of asthma. Obesity is 
associated with an abnormal persistent low level of inflammation and changes in adipocytes, 
macrophages and related cytokines are seen outside of asthma (259). Within adipose tissue 
macrophage subtypes both anti and pro inflammatory are important in mediation of obesity 
associated inflammation and are perhaps shaped by the characteristic presence of nutrients such as 
excess glucose and triglycerides (260, 261). Pro-inflammatory macrophages utilise the glycolytic 
pathway and the anti-inflammatory macrophages  use fatty acids as substrates. Obesity associated 
changes in immune cells and cytokines favour pro-inflammatory macrophage phenotype (262, 263).  
Both B and T cells are thought to play an important part in obesity related inflammation with T cells 
seen before macrophages in adipose tissue. T regulatory cells secreting Th2 profile cytokines (IL5, 
IL4, IL13) are found in lean tissue and decrease with increasing BMI in a manner like CD4 + T helper 
cells (Th2). In contrast CD8+ cells increase with obesity (264, 265).  
Obesity may increase susceptibility to infections from impaired immune defences (266, 267). It was 
identified as an independent risk factor during the 2009 H1N1 influenza outbreak (268), and 
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impaired function of anti-inflammatory lung macrophages in obese mice infected with influenza was 
associated with reduced survival (269). An association of nasopharyngeal colonisation with high BMI 
should prompt consideration of the benefit from pneumococcal vaccination, and may inform choice 
of targeted therapies in asthma, as obesity alters Th2 driven inflammation (62) (235). Clinically, 
weight loss is associated with improvement in asthma severity, control, and quality of life (55).  
This is an important finding as obesity is now a major public health concern, with increasing 
prevalence globally. Vaccination programmes are designed to reduce risk at both a population and 
individual level. If our findings are reproduced, the individual protection in this group of patients 
need consideration in guidelines and recommendations for pneumococcal vaccination. 
The following questions now require investigation:  
1. Does high BMI affect nasopharyngeal colonisation independent of asthma? 
2. Do people with obesity related asthma have an increased likelihood of nasopharyngeal 
colonisation? 
The first question may be addressed by setting a cohort study, defining groups based on BMI (<25, 
25-30 and >30) and following them for a period of 6 weeks with nasopharyngeal samples. Or by 
retrospective analysis of historic EHPC studies using a case control design – defining cases with a BMI 
25-30, >30 and controls with <25. BMI measurement has now been included in ongoing and future 
EHPC trials of healthy control participants and will assess colonisation outcomes prospectively in 
participants with a high BMI and compared to lean individuals. 
The second question about obesity asthma may be addressed by a case control epidemiological 
study – cases defined as BMI >25 and controls with BMI <25. Participants from a national registry or 
from data set of a tertiary clinic may be included.     
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 Systemic Responses 
The systemic responses to capsular IgG were similar in my cohort of asthma participants and healthy 
controls, although it was measured in only a subset of participants. The samples were collected at 
different time points (earlier for healthy controls), and these may be significantly higher if measured 
at day 29 in healthy controls. Similar data is not available at day 14 in asthma for comparison, and 
this may have shown a reduced response. Results require a cautious interpretation due to small 
numbers in the asthma cohort and differences in collection times.  
Despite an early clearance colonisation is immunogenic in people with well controlled asthma on ICS 
therapy. This may be attributed to a very well characterised and symptom free cohort of asthma 
participants, who had not received any oral corticosteroids (OCS) in the last 4 weeks and neither had 
more than one exacerbation in the preceding 12 months requiring OCS. This result may be different 
in severe asthma participants on high dose ICS and who often require multiple courses of OCS.  
The IgG to anti-pneumococcal proteins increased in colonised people with asthma as in healthy 
controls. The titres were measured against 27 pneumococcal proteins in both the cohorts. The 
response in titres to each protein was different in the two groups. This is an exploratory analysis 
with small number of participants in both cohorts. Healthy controls were part of a dose ranging 
study with a significant difference in inoculation dose and different sample collection time points for 
the two cohorts. The titres may have been higher and increase in IgG against more proteins may 
have been seen if measured at 4 weeks in healthy controls as in asthma. They may also be affected 
by the dose of inoculated bacterium. It is reassuring to see a similar trend for anti-pneumococcal 
protein IgG in people with well controlled asthma as they are potential targets for novel vaccines, 
although due to multiple statistical testing, this hypothesis-generating analysis may be affected by 
false-positive (type 2) errors.  
This generates the following questions:  
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1. Is colonisation immunogenic in severe asthma?  
2. Could the titres for anti-pneumococcal antibodies be used to compare vaccine response in 
asthma in comparison to healthy controls? 
3. Are the antibodies functionally comparable to healthy controls? 
A pilot case-control study of people with severe asthma and age matched healthy controls may 
address this. Severe asthma participants can be recruited from a tertiary asthma clinic with well-
defined inclusion criteria such as number of OCS courses in the last 12 months and no radiological 
evidence of structural lung disease within the last 2 years. Severe asthma participants for this study 
would require careful selection, as they often have co-existing conditions such as bronchiectasis 
which is recognised for immune deficiency. Age-matched healthy controls can be recruited from 
general population who have no underlying lung disease or any other medical condition which may 
compromise the immune system such as diabetes. Also, volunteers with past history of 
pneumococcal vaccination would have to be excluded. These antibodies are measured in clinical 
practice in severe asthma patient cohorts.  
The second question may be addressed by a pilot study of cases of asthma vaccinated with PCV. 
Although this may be challenging as they often receive PPV and have other underlying conditions 
such as bronchiectasis. Also, healthy control volunteers are not usually offered a pneumonia vaccine 
in the UK. Another option would be to study the response using EHPC – defining participants with 
asthma and healthy controls and offering them PCV. Measurements of IgG would be taken at 
baseline and 4 weeks after vaccination and colonisation status determined with nasopharyngeal 
samples. This would include carefully selected participants with moderate and severe asthma and 
healthy control.  
I aim to measure opsonophagocytic assays for these antibodies and also re-challenge some 
colonised participants to asses if these offer protection against future disease.     
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In Figure 2 in the introduction describes the possible mechanism of interactions during 
nasopharyngeal colonisation at the mucosa. I have adapted this and highlighted in bold the possible 
factors which may explain our findings.  
  
 





Goblet cells – reduced 




PAFR- provides attachment 
sites for the bacteria and 
promotes bacterial colonisation 
PAFR upregulation contributes 
to asthma pathogenesis by 
activation of immune cells, 
chemotaxis of eosinophils, and 
increased vascular permeability 
ICS reduce vascular 
permeability 
IL17- Not measured in this work, 
stored samples are available and 
could be looked at in future 
Increases neutrophil and 
macrophage recruitment 
facilitating bacterial clearance.  




Altered neutrophil activation, rolling and 
adhesion 
Neutrophils and T cells, including MAIT cells, 
were decreased in people with asthma 
compared to healthy controls. This data is not 
included in my thesis and is part of the 
manuscript submitted for peer review 
ICS lead to a reduction in inflammatory cells 
including T celss, mast cells and macrophages 
by inhibiting transcription of genes 
 
Eosinophilic inflammation - our 
patients had normal blood eosinophil 
levels - whichh may be due to adequate 
ICS therapy and good symptomatic 
control.  
ICS reduce the number of Eosinophils 





IL13, IL6, IL5 are all 
reduced by ICS  
B cells IL6 
ROS: reduced 
by ICS 
NO:  reduced 
by ICS  
IgG- in experimentally 
colonised people with asthma 
IgG titres to CPS and 
pneumococcal proteins is 
similar compared to healthy 
controls 
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Figure 21: Adapted from Figure 2 - Schematic diagram depicting the molecular interactions between 
S. pneumoniae and immune cells at the nasopharyngeal mucosa, with additions to include our 
findings  
The Platelet activating factor receptor (PAFR) provides increased attachment sites for the bacteria, 
thereby facilitating colonisation, and upregulation leads to asthma pathophysiology – this may 
explain increase bacterial colonisation in people with asthma. 
Interleukin (IL) 17 may be measured from stored samples later on – facilitates bacterial clearance 
following colonisation by recruitment of inflammatory cells and simultaneously contributes to 
asthma pathogenesis by promoting airway remodelling. 
IL5 cause chemotaxis of inflammatory cells specially eosinophils to the submucosa and mucosa 
causing airway inflammation – eosinophils were suppressed in our cohort of participants with well 
controlled, moderate disease.  
Serum IgG is important for protection against bacterial disease. When measured in a subset of our 
participants the response following colonisation was similar in people with asthma compared to 
healthy controls. 
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 BAL 
BAL samples are helpful to study the mucosal immune responses in the lungs. These can aid research 
for developing diagnostic techniques and studying airway remodelling secondary to new therapies. It 
is important to have a simple method without the risk of cross infection. Our sampling method with 
single use bronchoscopes is safe and effective in healthy controls. I can now extend this to asthma 
participants from challenge studies. Bronchoscopy would be offered to participants with mild well 
controlled disease and then extended to those on the severe spectrum of disease. There are several 
ongoing industry sponsored trials using bronchoscopy to study changes in airway mucosa following 
therapy with monoclonal antibodies.   
Possible areas that BAL sampling may address in asthma include:  
1. Improve understanding of alveolar mucosal immune response - secondary to ICS therapy 
and as a result of the condition. This can be achieved by using BAL sampling in healthy 
controls on ICS as described above and performing BAL samples in asthma participants on 
high and low dose ICS.  
2. Gain better knowledge of mucosal changes in asthma – such as airway remodelling, mucosal 
receptors, immune cells and antibodies present within the alveoli.  
3. Study the effect of therapies aimed at reducing airway inflammation and remodelling. This 
may be carried out in patients suitable for therapy with monoclonal antibodies before 
initiation of treatment and after  
 Challenges and strengths  
The main challenge I had to overcome was recruitment. Finding participants with objective evidence 
of asthma, on appropriate treatment and compliant with all our inclusion and exclusion criteria was 
a difficult task. To improve recruitment and complete the study I had to make several amendments 
as described in methods.  
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It is a strength of my study to investigate a well characterised cohort of asthma participants with 
detailed information on lung function, inflammation parameters, subjective and objective measures 
of control (ACT score and PEFR respectively), prescribed medication and smoking status, with follow 
up post challenge.  
Using the challenge model to study experimental colonisation with information on the dose of 
exposure, time of onset and duration is also a strength of our work.  
I have discussed the pathology of asthma a non-communicable disease and linked this to an 
infectious communicable disease, explaining how the two may be associated with each other.  
Excluding severe asthma participants with low lung function on high dose of ICS may have altered 
colonisation outcome and is a weakness of my study. I was  unable to include such individuals for 
safety reasons, due to an increased risk of exacerbation. However, I hypothesise for future studies 
that uncontrolled airway inflammation will lead to increased colonisation with rapid clearance. The 
effect of ICS at low, medium and high dose needs investigation in helathy volunteers with ethical 
approval. In addition measuring IL17 in participants with asthma may help address the part played 
by this cytokine in nasopharyngeal colonisation of pneumococcus.  
Comparative data for the healthy controls was available from historic EHPC studies where 
participants were inoculated at different times of the year, and the serum blood samples were 
collected at different times. The seasonal variation may affect colonisation rates and density as 
reported in studies.  
 Future 
This study demonstrates safe implementation of EHPC in people with mild to moderate asthma. This 
can be extended to people with more severe disease on high dose ICS, based on results of non-
interventional study. The model can also inform future vaccination studies in healthy controls and 
people with asthma to study immune responses post vaccination. The BAL sampling method can be 
used in asthma to study alveolar immune responses, to develop new therapies, investigate vaccine 
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targets and asses the response of new therapies on airway remodelling. The effect of BMI in healthy 
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 Participant information sheet 
Experimental Human Pneumococcal Challenge:  Effect of asthma on immune response to pneumococcus 
 Would you like to take part in our research?  
This information leaflet tells you how you could take part. A member of our team will also discuss it with 
you: please ask us if you have questions. You may want to talk to other people about the study: please do 
so. Take your time to decide if you want to be involved. 
What is the purpose of the study? 
We are developing a new vaccine to protect against a bacterium called Pneumococcus.  
Small numbers of these bacteria are often found in the nose. Usually, the carrier does not know the 
bacteria are there. In most adults this is present at least once per year and more often in children.  We 
think that small numbers of bacteria present in the nose (“nasal carriage’) can help to protect people 
against the disease. 
Mild infections with pneumococcus are very common, such as ear infections in children. But pneumococcus 
can also infect the lung (causing pneumonia) or the brain (causing sepsis). These severe infections are very 
uncommon in healthy adults: about 50 cases in Liverpool per year. However, those with asthma are more 
likely to become ill.  
We may be able to protect people against severe disease from pneumococcus using a vaccine which could 
be sprayed into the nose. We don’t yet know if this will work. 
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To test the idea, our research team want to study what happens when small numbers of the bacteria are 
put up the nose of those with asthma. We have already studied this using more than 500 volunteers and 
found this type of study to be safe. 
All of the volunteers we have studied so far have been “healthy volunteers”. In order to develop a vaccine 
that will protect those with asthma, we need to understand the immune responses in adults with asthma. 
Do I have to take part? 
No. Taking part in this study is voluntary. 
Why have I been asked to take part? 
We are looking for volunteers who have: 
• Mild, well controlled asthma 
• Do not smoke 
• Not had a life-threatening asthma attack 
• Not in close contact with children under 5 
Your participation will provide us with helpful information. We ensure that it is safe for you to take part and 
if we find any reason you may be at higher risk of infection, then we will not enrol you in the trial. 
You will not be eligible if: 
• You are aged more than 50 years 
• You are a regular smoker or have a significant history of daily smoking 
• You are in close contact with those who have lower immune levels (such as young children and 
people with chronic ill health) 
• You have taken part in similar research before 
• You are allergic to penicillin 
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• You have heart disease, or lung disease due to smoking 
• The study doctor thinks that a health condition, or medication means that you are at increased risk 
of infection 
• If you are pregnant. (We would advise you to use contraception during the study) 
What happens if I choose to take part? 
1. Consent –we ask you to sign a consent form when you are sure you want to take part. 
2. Taking samples – we take samples from the nose, throat and blood (see below).  We also do 
breathing tests (described later in the leaflet). Again, this is to check that you are well enough to take part 
in the study and to confirm a diagnosis of asthma if not done previously. 
3. Being given drops of pneumococcus in the nose - we put a few drops of liquid with a small number 
of bacteria in your nose. 
4. Monitoring– we will ask you to contact us daily (by phone or text) to make sure you are well.  
• We will ask you to complete a symptom questionnaire for seven days during the study. It asks 
simple questions such as do you have a cough, wheeze etc. 
• We will also ask you to provide details of someone who can be contacted in an emergency, as 
mentioned in the consent form. 
5. Monitoring visits – we take samples from your nose to see whether the bacteria are present and if 
your asthma is affected. 
 
This study takes less than four weeks. After six to twelve months we will invite some participants to repeat 
this study.  
A small number of participants may be allocated at random to receive drops of water in their nose rather 
than pneumococcus bacteria. This is called a placebo and will help us determine if people develop 
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symptoms (e.g. runny nose) because of the pneumococcus bacteria or simply as a reaction to our other 
study procedures. You will not know if you have received pneumococcus or a placebo until the end of the 
study and all participants will follow the same study protocol.  
What kind of samples do you take? 
• Samples from the nose: 
1. Nasosorption: This collects cells from your nose we place a small piece of blotting paper inside your 
nostril for a few minutes.   
2. Nasal probe: We run a small plastic rod along the inside of each nostril. 
 3. Nasal wash: We squirt a little salty water into your nose. After a few seconds the water runs out into a 
sample bowl. This will tell us about the bacteria in your nose and your immunity. 
• Throat swab: We wipe the back of your mouth with a sterile swab (like a cotton bud). The laboratory can 
use this to find out if there are any bacteria or viruses. 
• Blood samples: We take blood samples from a vein in your arm. We will never take more than 10 
teaspoons (50 ml).  
• Breathing tests: These tests are part of asthma care and you may have had them done before: 
1. Spirometry: This is a basic breathing test which measures the amount of air that can be blown out of the 
lungs. This is done using a spirometer and you will be asked to take a deep breath in and blow into the 
spirometer as hard and fast as you can until your lungs are completely empty. This routine will be repeated 
to ensure the results are consistent. Depending on the results you may be given an inhaler (bronchodilator) 
and have the test repeated 15-20 minutes later to see if there is any improvement. This is called 
reversibility.  
2. FeNO: This is a breathing test, done using a special machine. It involves blowing air out of the lungs into a 
machine at a steady rate. This test measures the inflammation in the lungs and is routinely used for 
diagnosis and monitoring of asthma in clinical practice. 
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3. Peak Expiratory Flow rate (PEFR): This is a measure of the fastest rate of air (airflow) that you can blow 
out of your lungs. It records airflow in litres per minute (L/min). It is measured using a peak flow meter 
which is a small device that you blow into. Participants will be given a peak flow meter and shown how to 
take a peak flow reading. It will be explained that the marker should be set to zero, take a deep breath and 
seal your lips around the mouthpiece and then blow as hard and as fast as you can into the device. They 
will be asked to note the reading on the chart provided. Each time we will ask you to check the reading 
three times and record the best of these three.  
 
What will happen to my samples? 
We will process your samples in laboratories at the Liverpool School of Tropical Medicine (LSTM) and at the 
Royal Liverpool University Hospital. We will measure the levels of bacteria and viruses in your nose and we 
will look in detail at how your immune system responds to the pneumococcus bacteria. 
To make full use of your samples we will store the remainder. In the future we can then go back to them 
with new tests to answer new questions. For some specialist tests we may send samples to laboratories in 
the UK and abroad. You may choose to gift your samples for future research. This may be used to study the 
DNA from your blood sample. This is mentioned in your consent form. If you choose not to donate your 
DNA you may still take part in the study. 
 
What will happen at each study visit?  
Initial Visit, Pre-
screen and Screening 
appointments 
(spread over about 
two weeks) 
We explain the study in detail, obtain your signed consent, ask some basic questions to 
ensure that you are eligible and do some breathing tests. We will also write to your GP 
to confirm some aspects of your medical history (e.g. which vaccinations you have had 
before) and inquire about asthma tests. 
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At the next visit we will do some more test as detailed earlier, check your blood 
pressure and temperature, listen to your heart and lungs, breathing tests (FeNO) and 
blood tests. We will also give you a PEFR meter to measure and record your peak flow 
rates at home. 
If you are well enough to take part in the study, we do the throat swab, nasal samples 
and other blood tests.  
We then book your next appointments. If you cannot come in on a specific date, we can 
be flexible to accommodate you. 




pneumococcus up the 
nose 
We collect samples as described earlier.  
We use a dropper to put a small amount of water containing a small number of bacteria 
into each nostril. Usually volunteers have no symptoms afterwards. There will be a 
doctor or nurse available by telephone 7 days a week to answer questions. We will give 
you a course of antibiotics to keep with you in case you are unwell, as well as a 
thermometer to check your temperature at home. Every day for the next week we will 
need to be in contact with you by phone or text to check that all is well. We advise 
following your personal asthma plan at all times and to seek medical help as 
necessary.  
 Up to six visits over the next five weeks 
Clinic Appointments 
on days 2, 7, 9 14, 22 
and 29 
At each visit, a number of samples will be taken which may include throat swab, 
nasosorption, nasal wash, nasal probe and blood tests 
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End of the first 
 study 
If our laboratory test finds that the pneumococcus bacteria stays in your nose, we will 
ask you to take a course of antibiotics to clear it. We may ask you to be in the re-
challenge study. 
 
 What about the re-challenge? 
We think that having small number of bacteria in your nose—even for a short time—might protect you 
against illness from this bacterium, possibly for a long time. But we cannot be certain. To test this, we may 
ask you to have the pneumococcus put into your nose a second time after a few months have passed. You 
do not have to take part in the re-challenge if you do not want to. These visits will take about 2 to 3 weeks. 




We make sure you are still fit to take part in the study by repeating the questions and 
examination done at the start of the first study. 
We do the throat swab, nasal wash and blood test, and ask you to monitor PEFRs. 
 1-7 days later 
Appointment for 
being given 
pneumococcus up the 
nose 
We use a dropper to put a small amount of water containing a small number of 
bacteria into each nostril, just like before. 
Each day for the next week we will ask you to contact the research team by phone or 
text for seven days to ensure that all is well and to check your temperature reading 
(again, antibiotics and a thermometer are provided in the study).  
 Daily phone call or text message for 7 days 
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Clinic appointments 
days 2, 7 and 14  
Samples as explained earlier. 
  
Visit 5: End of the 
study 
At the end of the re-challenge, after a final throat swab and nasal wash, if our 
laboratory confirm that you have had pneumococcus in your nose, we will ask you to 
take the antibiotic course to clear it. 
 
 
What are the risks of being in the study? 
Risks of being given live bacteria  
Because the bacteria are alive, there is a very small risk of infection to you or your close contacts. We do 
not expect anyone to develop an infection, but this is why we choose participants carefully and monitor 
them closely. We have experience of using this model safely in more than 500 healthy volunteers with no 
serious side effects. 
We provide a thermometer and antibiotics that treat these bacteria. We give you a separate leaflet which 
explains the safety precautions and what to do if you feel unwell. If you carry the pneumococcus bacteria in 
your nose at the end of the study, we will ask you to take the antibiotics to kill the bacteria. 
Risks of medical tests during the study  
The only side effect of nasal sampling is a little discomfort. Some people experience a runny nose. Some 
people can feel light-headed after blood tests and sometimes may have a bruise. All other tests are 
standard for asthma. If these results are outside the normal values, we will inform your GP. 
What if there is a problem? 
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You can contact the research team 7 days a week by phone to answer your questions and arrange to see 
you as necessary. We would recommend using and following your personal asthma action plan at all times. 
What if I wish to complain? 
  
If you wish to complain about any aspect of the study, you can contact the study doctor. You may also use 
the Royal Liverpool University Hospital’s independent complaints department (contact number 
01517064903). Making a complaint will not affect the medical care you receive now or in the future. 
What if I change my mind or want to stop? 
Even if you do start in the study you are free to stop at any time and without giving a reason. If you decide 
not to take part, or wish to withdraw from the study, this will have no effect on your future health care. 
If you decide to stop, we will continue to use the samples and information that we have already collected 
unless you tell us not to. You will be paid for the visits completed up to that point.  
Will my details be kept confidential? 
Yes. For safety, we collect information about your medical history and contact details before you take part. 
The clinical research team use this information to check you are healthy and to contact you when needed. 
We will ask your permission to ask your GP to share some of your medical history with us.  
We will also collect information which allows us to understand more about the samples, for example, your 
age or sex. However, those outside of the clinical team are never given information that can identify you. 
Your samples are given a unique number and your name is not used. 
We do not expect to find anything which would affect your health care. If we do, we will let you and your 
GP know about it. 
All data will be collected and stored at the Royal Liverpool University Hospital and the Liverpool School of 
Tropical Medicine. It will be stored for a minimum period of 10 years. Your medical notes and research data 
may be looked at by those who monitor the research. 
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Are there any benefits to taking part? 
There are no direct benefits to you. You will be a part of what we believe is a valuable research study that 
may help us to improve the medical care of people with asthma. 
How much will I be paid? 
The money you are paid is compensation for inconvenience, loss of income and your time. The first 
payment will be made at the end of part one. If you are eligible and choose to take part in the second 
study, you will receive a second payment at the end of part two. If you receive a placebo instead of 
pneumococcus the payment is unchanged. Our payments are listed below: 
 
First Study Visit length  
Initial Visit 45 min - 
Pre-screen appointment 60 min £40 
Screening appointment  30 min £30 
Inoculation with pneumococcus appointment. This includes you making daily 
telephone/text message contact for the first 7 days.  
(We will withhold £5 per day if you do not contact us) 
30 min £50 
Clinic appointments for samples on days 2 and 7 30 min £20 
Clinic appointment for samples on day 9  20 min £15 
Clinic appointments for samples on days 14 and 22 (not all participants will 
be called for day 22) 
15 min £10 
Clinic appointment for samples on day 29  25 min £20 
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Re-challenge   
Re-challenge study pre-screen. 45 min £30 
Inoculation with pneumococcus appointment. This includes you making daily 
telephone/text message contact for the first 7 days.  





Re challenge study clinic visit day 2, 7 and 14 20 min £15 
 
 
After you have had time to read the information leaflet a member of our team will discuss the study with 
you: please ask us if you have questions. You may want to talk to other people about the study: please do 
so. Take your time to decide if you want to be involved 
Contact details  
General questions: please contact the research team on 0151 706 3381 during normal working hours. Web 
site: ******* 
Emergency contact details at any time 7 days a week:  
Mobile: 07595463833 
Royal Liverpool Hospital Switchboard: 0151 706 2000.  
Please ask for the study team (“EHPC team” or “Pneumonia research team”) 
 
The Chief Investigator for this study is Dr Jamie Rylance. You may contact him at the Liverpool School of 
Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. Telephone: 0151 705 3775. 
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This research is sponsored by the Liverpool School of Tropical Medicine and the Royal Liverpool and 
Broadgreen University Hospitals. It is funded by the Medical Research Council and The Bill and Melinda 
Gates Foundation. The research has been reviewed for scientific content by an external panel. 
Royal Liverpool University Hospital Independent Complaints Department 0151 706 4903 
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Appendix B 
Invitation letter from Primary Care 
To be printed on GP Letter Headed Paper>  
<Insert Patient Title and Name> 
<Insert Patient Address1> 
<Insert Date> 
Dear <Insert Patient Title and Name> 
We want to invite you to be part of a research study. 
A group of researchers from the Liverpool School of Tropical Medicine, is trying to find out why 
people with asthma are more likely to get pneumonia. The research is done at the Royal Liverpool 
University Hospital. 
As your GP, we are not linked with the study. But we are helping to give details of the research to 
people who might be able to take part. We will not pass any of your details to the research team: 
your details are confidential. 
The details are explained in the participant information sheet attached with this letter. This study 
has been reviewed and approved by the National Research Ethics Service Committee.  
Whether you agree to take part of not is entirely up to you. It makes no difference to the care you 
receive at the GP or anywhere else. 
If you do take part, you will be paid for your time and inconvenience. 
To find out more about the study please:  
- Call 0151 706 4856 
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Dr <Insert GP Title and Name> 




                                                   
 
                                         
 





Dear Dr ______________________ 
Your patient _______________________________________________,  
DOB _______________ has agreed to participate in pneumonia vaccine research : Experimental 
Human Pneumococcal Carriage: Effect of asthma on immune response to pneumococcus  
This study involves inoculation with pneumococcal bacteria and monitoring over 4 weeks for 
experimental carriage of the bacteria.  
We appreciate you are busy and would be grateful if, you would please complete, sign, date and 
stamp the attached forms or print a relevant summary of their records so that the participant may 
commence the study as early as next week if possible. This will ensure safety of the participant and 
provide the necessary information to check that your patient is eligible to participate. Please return 
the completed forms by fax to Catherine Lowe on (0151) 706 4856.  
Thank you. 
If you have any concerns or questions regarding this study, please contact us on 0151 706 3381 
Sister Catherine Lowe 
catherine.lowe@rlbuht.nhs.uk 
Tel (0151) 706 3381 
Fax (0151) 706 4856 
Mobile: 07912053981 
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Medical Report to be completed by the General Practitioner 
 
General Medical History Please Circle Please Provide Details 
Is the above person registered 
with your practice and do you 
have their full medical record for 




A minimum of 12 months history is required 
before participants can take part in this 
research. Please contact us if the notes are 
not available but request the records so the 
questionnaire can be completed as soon as 













If YES, please provide a copy of any 
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Does the patient have an 
immunosuppressive condition? 
(Including diabetes, active 
malignancy, immunosuppression 










Has the patient been treated for 
an asthma exacerbation in the 





If YES, please state how many times in the last 
twelve months? 














Details (or please attach copy of latest 
prescription) 
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Is there objective evidence that 
the patient has previously had 
pneumococcal disease? (Culture-









Has the patient received a 
pneumococcal vaccine at any 










Are you aware of any reason why 
this patient might not be 














                                                   
 
                                         
 
Appendices  – Effect of Asthma on Immune Response to Pneumococcus  Page 183 
 
Appendix D 
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Appendix E 
 PEFR Diary 
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Appendix F 
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Appendix G 
Asthma Control Test   
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Appendix H 
Participant Inoculation Leaflet                             
EXPERIMENTAL HUMAN PNEUMOCCAL CARRIAGE: 
THE EFFECT OF ASTHMA ON IMMUNE RESPONSE TO PNEUMOCOCCUS 
Information Sheet 
EMERGENCY RESEARCH TEAM 
7 days a week – phone number 
OR CALL 
0151 706 2000 
Hospital Switchboard 
Ask for XXXXXXXXXXXXX 
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What should I do?  
If you have any of the above symptoms, we would ask that you should contact the research team on 
the following numbers without delay  
Xxxxx xxx xxx 7 days a week  
0151 706 2000 Hospital switchboard - ask for xxxxxxxxxxxxx who will be available by telephone 7 
days a week for advice.  
What if I feel very unwell?  
In the unlikely event you feel very unwell, the research team emergency number (xxxxx xxx xxx) is 
available seven days a week. If for any reason you are unable to make contact with the team (or are 
not able to access a phone) we recommend that you start taking the antibiotics immediately (one 
tablet (500mg) of AMOXICILLIN to be taken three times per day) and attend your nearest Emergency 
department.  
What do I tell the doctor?  
If, for any reason you have to attend your doctor or the hospital you need to inform them that: You 
have had live Streptococcus pneumoniae inoculated into your nose on ___/___/_______ as part of a 
clinical study. The bacteria you carry are fully sensitive to amoxicillin and you have no history of 
allergy to this antibiotic.  
Do I need to do anything if I feel well?  
We ask that for the first 7 days you text or phone the research nurse by 12noon every day on the 
following number: xxxxx xxx xxx. .  
This is to ensure that you are not experiencing any problems. If we do not hear from you by 12noon, 
we will contact you to make sure you are not experiencing any problems. In the event that we 
cannot contact you, your next of kin will be contacted. 
 
Things you should know........  
Following inoculation with pneumococcus  
After the pneumococcus is put into your nose it is possible that it may cause an infection. Although 
this is very unlikely it is sensible that you familiarise yourself with symptoms or signs that may 
indicate infection to make sure they are recognised and treated early.  
Keep your thermometer, antibiotics and contact numbers with you at all times during the study.  
WHAT SHOULD I LOOK OUT FOR?  
If you feel generally unwell or have any of the following:  
• Fever (temp>37.5 ˚C)  
• Shivering  
• Headache  
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• New rash  
• Drowsiness  
• Cough  
• Earache  
• Wheeze 
• Shortness of breath 
 
If you have any of the symptoms or signs marked in bold please call the emergency number 
immediately.  
                                                   Xxxxx xxx xxx  
                                                   7 days a week  
                         OR Phone 0151 706 2000 and ask for xxxxxxxxxxxxx 
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Appendix I 
Daily Symptom Log  
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Appendix J 
Participant trial Business card  
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    Appendix K  
Reminder Letter to participants from GP  
       <To be printed on GP Letter Headed Paper> 
 
<Insert Patient Title and Name> 
<Insert Patient Address4>      <Insert Date> 
 
 
Dear <Insert Patient Title and Name> 
 
We want to invite you to be part of a research study. Please accept our apologies if you have already 
responded to the initial letter sent out by the practice for this study.  
A group of researchers from the Liverpool School of Tropical Medicine, is trying to find out why 
people with asthma are more likely to get pneumonia. The research is done at the Royal Liverpool 
University Hospital. 
As your GP, we are not linked with the study. But we are helping to give details of the research to 
people who might be able to take part. We will not pass any of your details to the research team: 
your details are confidential. 
The details are explained in the participant information sheet attached with this letter. This study 
has been reviewed and approved by the National Research Ethics Service Committee.  
Whether you agree to take part of not is entirely up to you. It makes no difference to the care you 
receive at the GP or anywhere else. 
If you do take part, you will be paid for your time and inconvenience. You do not have to reply or 
respond to this letter if you did so the first time.  
 
To find out more about the study please:  
- Call 0151 706 3381 
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<Insert GP Signature> 
 
Dr <Insert GP Title and Name> 
< Insert Name of Practice >           
